Systematic review, meta-analysis and meta-regression by Steinvorth, Simon Moritz
AUS DEM INSTITUT FÜR MEDIZINISCHE STATISTIK 
(PROF. DR. SC. HUM. T. FRIEDE) 
IM ZENTRUM INFORMATIK, STATISTIK UND EPIDEMIOLOGIE 
DER MEDIZINISCHEN FAKULTÄT DER UNIVERSITÄT GÖTTINGEN 
 
Explaining temporal trends in annualized relapse rates in placebo groups of  
randomized controlled trials in relapsing multiple sclerosis: 
Systematic review, meta-analysis and meta-regression 
 
 
INAUGURAL – DISSERTATION 
 
 
zur Erlangung des Doktorgrades 
der Medizinischen Fakultät der 














Diese Arbeit wurde angefertigt unter Anleitung der gleichberechtigten Co-Betreuer Prof. Dr. 
Tim Friede (Institut für Medizinische Statistik, Universitätsmedizin Göttingen) und PD Dr. 
Sebastian Straube (Institut für Arbeits-, Sozial- und Umweltmedizin, Universitätsmedizin 























Dekan:     Prof. Dr. rer. nat. H. K. Kroemer 
 
I. Berichterstatter:   Prof. Dr. sc. hum. T. Friede 
II. Berichterstatter:   Prof. Dr. med. M. Simons 
III. Berichterstatter:   Prof. Dr. med. M. Oppermann 
Tag der mündlichen Prüfung:  21. Januar 2014 
 
3 
Table of Contents 
1 Introduction .................................................................................................................... 5 
 Aim of this study ............................................................................................................ 5 
 Statement of authorship .................................................................................................. 5 
 Multiple sclerosis ........................................................................................................... 6 
1.3.1 Epidemiology ........................................................................................................... 6 
1.3.2 Pathogenesis, clinical symptoms and phenotypes.................................................... 7 
1.3.3 Treatment ............................................................................................................... 11 
1.3.4 Guidelines on clinical investigation for MS treatments ......................................... 11 
1.3.4.1 Expanded Disability Status Scale .......................................................................... 11 
1.3.4.2 Annualized Relapse Rate ....................................................................................... 12 
2 Methods ........................................................................................................................ 13 
 Strategy ......................................................................................................................... 13 
 Literature search ........................................................................................................... 13 
 Acquisition of data ....................................................................................................... 14 
2.3.1 Outcome data ......................................................................................................... 14 
2.3.2 Oxford Quality Scale ............................................................................................. 15 
2.3.3 Study design features ............................................................................................. 16 
2.3.4 Patient characteristics at baseline ........................................................................... 17 
 Data analysis ................................................................................................................ 17 
2.4.1 Outcome data ......................................................................................................... 18 
2.4.2 Oxford Quality Scale ............................................................................................. 18 
2.4.3 Study design features ............................................................................................. 18 
2.4.4 Patient characteristics at baseline ........................................................................... 19 
2.4.5 Epoch analyses ....................................................................................................... 20 
2.4.6 Statistical considerations ........................................................................................ 21 
2.4.6.1 Regression models ................................................................................................. 21 
2.4.6.2 Meta-regression of statistically significant temporal trends .................................. 21 
3 Results .......................................................................................................................... 23 
 Literature search ........................................................................................................... 23 
 Outcome data ................................................................................................................ 25 
3.2.1 Trial ARRs in placebo groups ................................................................................ 25 
3.2.2 Duration of placebo-controlled follow-up ............................................................. 26 
 
4 
3.2.3 Number of patient years considered for the calculation of trial ARRs .................. 27 
3.2.4 Dispersion of trial ARRs in placebo groups .......................................................... 28 
 Oxford Quality Scale .................................................................................................... 29 
 Study design features ................................................................................................... 30 
3.4.1 Data on eligibility criteria ...................................................................................... 30 
3.4.1.1 Pre-trial ARR ......................................................................................................... 35 
3.4.1.2 Eligible age ............................................................................................................ 37 
3.4.1.3 Eligible scores on the EDSS .................................................................................. 38 
3.4.1.4 Minimum number of days without relapse ............................................................ 39 
3.4.1.5 Minimum number of days without the use of high-dose steroids .......................... 40 
3.4.2 Additional study design features ............................................................................ 41 
 Patient characteristics at baseline ................................................................................. 43 
3.5.1 Pre-trial ARRs ........................................................................................................ 43 
3.5.2 Age ......................................................................................................................... 46 
3.5.3 Disease duration ..................................................................................................... 48 
3.5.4 Scores on the EDSS ............................................................................................... 50 
3.5.5 Gender distribution ................................................................................................ 52 
 Epoch analyses ............................................................................................................. 53 
 Meta-regression of statistically significant temporal trends......................................... 55 
4 Discussion .................................................................................................................... 56 
5 Summary ...................................................................................................................... 60 
6 List of Abbreviations .................................................................................................... 61 
7 Index of Figures ........................................................................................................... 62 
8 Index of Tables ............................................................................................................. 63 
9 References .................................................................................................................... 64 
10 Appendix ...................................................................................................................... 73 
 Poster P1022 for ECTRIMS [Steinvorth et al. 2012] ................................................ 73 





 Aim of this study 
Across randomized controlled trials (RCTs), a downward trend in trial annualized relapse rates 
(ARRs) of placebo patients has recently been observed [Nicholas et al. 2011a; Inusah et al. 
2010]. The trial ARRs of placebo patients improve significantly and increasingly so, although 
they receive no active agent [Nicholas et al. 2012]. This trend has severe implications: The 
inter-trial comparability of earlier and later trials is disputed [Nicholas et al. 2011a]. 
Consequently this complicates the comparison of new products with established competitors in 
lack of head-to-head data [Nicholas et al. 2011a]. In addition, new trials will require bigger 
sample sizes in order to achieve comparable statistical power [Nicholas et al. 2011a]. 
The aim of this dissertation is the description of this yet unexplained downward trend in placebo 
trial ARR and to investigate potential causal factors. It uses published, peer reviewed RCTs 
from 1982 to 2012 and analyzes factors such as patient baseline characteristics, eligibility 
criteria and other study design features, investigating possible factors contributing to this 
phenomenon. 
 Statement of authorship 
The subject of this dissertation was a suggestion of my doctoral advisors, Prof. Dr. sc. hum. T. 
Friede (TF), head of the Institute of Medical Statistics (German: Institut für Medizinische 
Statistik) at University Medical Center Göttingen and PD Dr. phil. S. Straube from the Institute 
of Occupational, Social and Environmental Medicine at University Medical Center Göttingen, 
in 2011. Both acted as co-supervisors throughout the whole process.  
I alone am responsible for the introduction, the literature search and the collection of data – 
although all data was later double-checked by either of three colleagues from the Institute of 
Medical Statistics, namely Dr. phil. C. Röver (CR), S. Schneider (SCH) and M. Butter (MB). I 
am also responsible for the data analysis, although I created the graphics mostly with assistance 
from CR, who wrote the software codes for the meta-regression, the forest and bubble plots. I 
received valuable insight from CR and TF on statistical questions more than once. TF, SS and 
CR advised me on the discussion, though I am responsible for the version proposed here. 
Some of the findings presented in this dissertation were published as a poster (see appendix) 
during the 28th congress of the European Committee for Treatment and Research in Multiple 
Sclerosis (ECTRIMS) from 10 – 13 October 2012 in Lyon, France, in collaboration with Dr. R. 
Nicholas FRCP (RN) at the Imperial College Healthcare NHS Trust in London, UK. The 
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 Multiple sclerosis 
Multiple sclerosis (short: MS; Latin: Encephalomyelitis disseminata) is a chronic inflammatory 
autoimmune disease, which so far remains incurable. It is the most common demyelinating 
disease of the central nervous system (CNS) and the leading cause of non-traumatic disability 
among young adults in the United States of America [Wakerley et al. 2012; European 
Medicines Agency 2006; Fox et al. 2006]. The key diagnostic criterion of MS is the 
dissemination of demyelinating CNS lesions both in time and space [Polman et al. 2011]. The 
etiology of MS is unknown, there is however evidence of a combination of genetic and 
environmental factors [Wakerley et al. 2012]. 
1.3.1 Epidemiology 
The median incidence of MS worldwide is estimated at 2.5/100,000 [World Health 
Organization and Multiple Sclerosis International Foundation 2008] and is speculated to be 
increasing, a notion which so far proved difficult to substantiate [Orton et al 2006]. The female 
to male ratio in incidence of MS is increasing [Trojano et al. 2012; Koch-Henriksen and 
Sørensen 2010; Alonso and Hernán 2008; Orton et al. 2006]. Global prevalence is estimated at 
30/100,000 worldwide [World Health Organization and Multiple Sclerosis International 
Foundation 2008], with a wide range of variability in different regions; Germany for instance 
has a MS prevalence of 149/100,000 while the American continents report a combined 
prevalence of 8.3/100,000 [World Health Organization and Multiple Sclerosis International 
Foundation 2008]. Possible geographical patterns of epidemiological data, such as the 
hypothesis of a global latitude gradient with lower prevalence seen closer to the equator, are 
currently subject of scientific discussion, especially in respect to unanswered etiological 
questions [O'Gorman et al. 2012]. 
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1.3.2 Pathogenesis, clinical symptoms and phenotypes 
The formal pathogenesis of MS is presumed to be an immune dysregulation, predominantly 
involving T-lymphocytes [Hafler 2004; Wakerley et al. 2012]. T-cells that were primed in the 
peripheral blood recognize components of the myelin sheaths as an antigen, subsequently 
releasing a number of cytokines and thus activating macrophages and B-lymphocytes 
[Wakerley et al. 2012]. This results in the destruction of oligodendrocytes that build myelin 
sheaths, described as demyelination. Although the local inflammation causing the 
demyelination eventually resolves and remyelination sets in, damage to the underlying nerve 
fibres can not always be escaped [Wakerley et al. 2012].  
Demyelination affects the ability of proper neuronal signal conduction [Wakerley et al. 2012; 
McDonald and Sears 1970], oftentimes leading to an acute exacerbation of symptoms, known 
as a relapse. Symptoms can also develop progressively over time, without an abrupt onset 
[Deutsche Gesellschaft für Neurologie 2012; Polman et al. 2011; Poser 1983].  
These symptoms vary as much as the locations of the CNS lesions. Common symptoms include 
numbness, paresthesia, weakness, spasticity, dyscoordination, visual loss, binocular diplopia, 
bladder dysfunction, bowel dysfunction, and sexual dysfunction, as well as cognitive 
impairments, depression and fatigue [Fox et al. 2006]. 
A relapse is defined as the occurrence of one or more symptom, lasting at least 24 hours, not 
explicable by fever or infection, and preceded by a relatively stable or improving neurologic 
state of at least 30 days, as reported by the patient or objectively observed [Deutsche 
Gesellschaft für Neurologie 2012]. However, while some MS patients present only relapses and 
others only progressively developing symptoms, some do present both. 
Lublin and Reingold defined four standardized disease courses to distinguish between clinical 




Relapsing-remitting MS (RRMS) 
 
 
Figure 1: RRMS [Lublin and Reingold 1996, p908, modified] 
The axis of abscissae represents time, the axis of ordinates the level of the patient’s disability. 
 
 
“The defining elements of RRMS (also: exacerbating-remitting MS) are episodes of acute 
worsening of neurologic function followed by a variable degree of recovery, with a stable 
course between attacks“ [Lublin and Reingold 1996, p908]. About 85% of MS patients 
experience this course during disease onset [Fox et al. 2006]. 
Secondary-progressive MS (SPMS) 
 
 
Figure 2: SPMS [Lublin and Reingold 1996, p909, modified] 





After an initial relapsing-remitting disease course, neuronal functioning begins to progressively 
worsen between relapses. Eventually, the disease progresses with or without occasional 
relapses, minor remissions, and plateaus [Lublin and Reingold 1996]. 50% of all RRMS patients 
eventually develop SPMS within ten years [European Medicines Agency, 2006]. 
Primary-progressive MS (PPMS) 
 
 
Figure 3: PPMS [Lublin and Reingold 1996, p909, modified] 
The axis of abscissae represents time, the axis of ordinates the level of the patient’s disability. 
 
 
Nearly continuous „disease progression from onset of the disease with occasional plateaus and 




Progressive-relapsing MS (PRMS) 
 
Figure 4: PRMS [Lublin and Reingold 1996, p910, modified] 
The axis of abscissae represents time, the axis of ordinates the level of the patient’s disability. 
 
 
„Progressive disease from onset, with clear acute relapses, with or without full recovery; 
periods between relapses characterized by continuing disease progression” [Lublin and 
Reingold 1996, p909]. However, the German Society of Neurology (German: Deutsche 
Gesellschaft für Neurologie) does not list this disease course in their diagnostic guideline 
[Deutsche Gesellschaft für Neurologie 2012]. 
The term Relapsing MS (RMS) is defined by the presence of relapses, even though it is lacking 
a consistent definition:  Some trials explicitly investigating Relapsing MS included only patients 
with RRMS and SPMS (for example Saida et al. 2012; study ID #56), some also included 
patients with PRMS (O’Connor et al. 2011; study ID #53), others did not specify what was 
meant by the term (Jacobs et al. 1996; study ID #12). In the following, the term is referred to 
as the subsumption of all phenotypes of confirmed MS that share the occurrence of relapses. In 




There is yet no curative approach in the treatment of MS. Therefore disease management 
remains the main objective in therapy development [European Medicines Agency 2006]. This 
includes shortening the duration of relapses, alleviating the severity of the symptoms, 
preventing the occurrence of relapses, delaying the long-term accumulation of disability, and/or 
improving residual neurological impairment [European Medicines Agency 2006]. 
A number of therapies have achieved some of these goals in clinical trials. The use of high-dose 
corticosteroids, for instance, is recommended in the case of an acute relapse [Deutsche 
Gesellschaft für Neurologie 2012; Multiple Sclerosis Therapy Consensus Group 2008]. 
Interferon-beta is recommended as a first-line therapy in RMS and CIS [Multiple Sclerosis 
Therapy Consensus Group 2008]. Glatiramer Acetate is recommended in RRMS and CIS 
[Multiple Sclerosis Therapy Consensus Group 2008]. Other pharmaceuticals include 
Natalizumab, Fingolimod, Mitoxantrone and Cyclophosphamide, which are recommended as 
second-line or escalating therapies under specific restrictions [Multiple Sclerosis Therapy 
Consensus Group 2008]. Most of these therapies have an effect on relapses, particularly their 
frequency and/or severity [Nicholas et al. 2011b; Deutsche Gesellschaft für Neurologie 2012; 
Multiple Sclerosis Therapy Consensus Group 2008]. As they target the immune response 
driving MS related CNS damage, they are subsumed as disease modifying treatments. 
1.3.4 Guidelines on clinical investigation for MS treatments 
Randomized, controlled trials (RCTs) represent the gold standard of clinical trials in evidence-
based medicine. The Committee For Medicinal Products For Human Use (CHMP) of the 
European Medicines Agency provides guidelines on the clinical investigation of medicinal 
products in RCTs. The guideline for medicinal products for the treatment of MS [European 
Medicines Agency 2006] elaborates, among other details, on qualified outcome measures: It 
states that primary efficacy parameters should assess disability progression, and in patients with 
RMS also the frequency of relapses. The CHMP suggests the Annualized Relapse Rate (ARR) 
as the outcome of choice when assessing relapses and Kurtzke's Expanded Disability Status 
Scale (EDSS) when assessing progression of disability [European Medicines Agency 2006]. 
Parallel group, placebo-controlled study designs are currently favored among investigators, 
although in discussion [Nicholas and Friede 2012]. 
1.3.4.1 Expanded Disability Status Scale 
The EDSS [Kurtzke, 1983] measures neurological functionality in seven distinct systems 
(pyramidal functions, cerebellar functions, brain stem functions, sensory functions, bowel and 
bladder functions, visual functions and mental functions) and processes them into ordinal 
grades ranging from 0.0, equivalent to a normal neurologic exam, over several grades of 
disability up to 10.0, equivalent to death due to MS. It has been criticized for its inadequate 
assessment of the upper limb functions and cognitive impairment [European Medicines Agency 
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2006], but none of the alternative disability assessments, such as the Multiple Sclerosis 
Functional Composite (MSFC) or the Multiple Sclerosis Severity Score (MSSS), could achieve 
similar support in the scientific community [D'Souza et al. 2008]. 
1.3.4.2 Annualized Relapse Rate 
The ARR derives itself from a number of relapses divided by the follow-up time, normalized 
to the time of one year. It is used for patient groups by counting the total number of relapses of 
all group members and dividing the sum by the total accumulated patient-time in which these 
relapses occurred, normalizing it to the time of one year. Its main advantage over other relapse-
related outcomes, such as the number of relapse-free patients or the time to first relapse, is that 
it takes more than just the first relapse into account [Wang et al. 2009]. Although ARRs in RMS 
patients were found to be age- and time-dependent [Tremlett et al. 2008], constant ARRs are 
assumed in the design and analysis of trials in RMS [Wang et al. 2009]. 
In this study, the term trial ARR refers to the ARR measured over the course of the trial, from 
randomization to the end of the trial. The term pre-trial ARR refers to the ARR before 






The first aim of this study was an analysis of ARRs across peer reviewed publications to answer 
the question of the described downward trend can be confirmed in a different, preferably larger 
set of studies than those it has previously been observed in. After confirmation of such a 
downward trend, this study examined other factors and traced other temporal trends that might 
be associated with the phenomenon in question. Those factors that demonstrated statistically 
significant temporal trends were then further analyzed in a meta-regression, in order to 
investigate a potentially causal relationship with the downward trend in trial ARR. 
 Literature search 
The literature search used three scientific bibliographic online data bases (The Cochrane 
Library, Web of Science, Medline/PubMed), aiming to identify placebo-controlled, double-
blind RCTs in MS with data on trial ARR or, alternatively, data that allowed trial ARR to be 
calculated. 
The Cochrane Library 
The search conducted in the Cochrane Library (URL: http://thecochranelibrary.com/) yielded 
88 hits for the search terms MS in Title, Abstract or Keywords, relapsing in Title, Abstract or 
Keywords, placebo in Title, Abstract or Keywords and rate; 
143 results for the search terms multiple sclerosis in Title, Abstract or Keywords, patients in 
Title, Abstract or Keywords, placebo-controlled in Title, Abstract or Keywords, remitting in 
Title, Abstract or Keywords and double-blind in Title, Abstract or Keywords; 
and 15 results for the search terms multiple sclerosis in Title, Abstract or Keywords, 
exacerbation rate in Title, Abstract or Keywords, clinical in Title, Abstract or Keywords, 
reduction in Title, Abstract or Keywords, and control in Title, Abstract or Keywords. 
Web of Science 
The search in Web of Science yielded 320 hits for the search terms relapsing in Topic, placebo 





The Medline/PubMed search [URL: http://www.ncbi.nlm.nih.gov/pubmed/] produced 120 hits 
for the search terms multiple sclerosis in Title or Abstract, relapse rate in Title or Abstract, and 
placebo in Title or Abstract; 
54 results for the search terms multiple sclerosis and relapsing and placebo in records from 
2011/09/20 to 3000 in Date – Publication. This last search string was entered at a later point in 
time than the first to update the resulting trunk of trials at the end of the data acquisition period. 
 
 
Figure 5: Flowchart of the literature search 
 
 
All multiple entries, trials that were not double-blind, placebo-controlled RCTs in RMS, cross-
over trials, non-human trials, trials where the control group received a form of active therapy 
(i.e. trials of add-on therapies) and open label extension studies of RCTs were excluded after 
exploration of the abstract or, if that proved inconclusive, the full text of the paper. 
 Acquisition of data 
As a general procedural precept, mean values were extracted along with standard deviations 
(SD), or median values and interquartile ranges (IQR), when available. Where standard 
deviations were not available, they were calculated from p-values, standard errors (SE), 
confidence intervals (CIs) or t-statistics [Higgins and Green 2011, Part 2, Chapter 7.7: 
Extracting study results and converting to the desired format]. All extracted data from the 
papers were verified by either of three colleagues in the Institute of Medical Statistics (CR, 
SCH or MB). 
2.3.1 Outcome data 
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The following data, if available, were extracted from the papers: 
 
 The trial ARR in placebo groups, 
 the associated number of placebo patients, 
 the duration of placebo-controlled follow-up. 
 
 If a trial ARR was not stated, it was calculated by dividing the total number of relapses by the 
number of patients in the placebo group, giving a mean relapse rate, and then extrapolating to 
an annualized relapse rate by correcting for the time over which relapses were observed. When 
an adjusted rate was given, i.e. adjusted to age, sex or other parameters, as well as an unadjusted 
rate, the latter was preferred. Whenever trials distinguished between different intensities of 
relapses, the total sum of relapses was counted irrespective of severity. For ARRs without a 
quoted standard error, errors based on a Poisson approximation were derived, assuming a 
variance equal to the mean value. 
In one instance [Miller et al. 2012] one data point (the standard deviation of the trial ARR of 
the placebo group) seemed implausible to the author and his supervisors. Since no published 
correction could be found and the authors of the publication in question did not reply to a request 
to clarify this point, this value was omitted. 
2.3.2 Oxford Quality Scale 
The Oxford Quality Scale (short: OQS; also sometimes called Jadad scale) is the most 
commonly used, most frequently cited scale to assess the quality of RCTs [Olivo et al. 2008]. 
It was originally developed by Jadad and colleagues [Jadad et al. 1996] and evaluates RCTs 
with regard to their documentation of randomization, blinding procedures and withdrawals or 
drop-outs on an ordinal scale between 0 and 5. 
The score on the OQS was assessed for all papers included in this study. If a paper described 
the method for randomization in detail and it was appropriate, 2 points were given; if 
randomization was merely stated, 1 point; no points, if randomization was not mentioned at all 
or described, but inappropriate [Jadad et al. 1996]. The procedure for double blinding was 
analogous [Jadad et al. 1996]. If a paper described the number of drop-outs or withdrawals 
along with the reasons for the drop-out/withdrawal, 1 point was given [Jadad et al. 1996], 




2.3.3 Study design features 
Data on eligibility criteria 
The following data, if available, were extracted from the papers: 
 
 The number of eligibility criteria, 
 the number of words and characters describing these criteria, 
 trial inclusion criteria concerning age, 
 trial inclusion criteria concerning pre-trial ARR, 
 trial inclusion criteria concerning scores on the EDSS, 
 trial inclusion criteria concerning the time since the last relapse, 
 trial inclusion criteria concerning the time since the last use of high-dose steroids. 
 
For the count of eligibility criteria, all inclusion criteria were counted, unless they were 
mutually exclusive, and all exclusion criteria were counted, unless they matched any inclusion 
criteria already counted, similar to the approach established by Clisant and colleagues [Clisant 
et al. 2012]. Only criteria applying to patients with RMS were counted. Having the correct 
diagnosis to be included to a study was counted as one criterion. 
To determine the number of words or characters used to describe the eligibility criteria, all 
sentences or tables containing these criteria were copied into a word processing program 
(LibreOffice 3.5.2.2) and counted automatically. Features due to editing, such as spaces and 
bullets, were not included in the count. Captions of inclusion or exclusion criteria did count. 
When supplementary material offered more detailed information on eligibility criteria than the 
main publication, it was used instead of the latter. 
Additional study design features 
The following data, if available, were extracted from the papers: 
 
 The number of treatment arms in the trial, 
 the allocation ratio of recruited patients to these arms. 
 
When the allocation ratio was not explicitly given in a paper, it was derived by the numbers of 
patients in the trial arms. 
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2.3.4 Patient characteristics at baseline 
The following baseline data, if available, were extracted from the papers: 
 
 Age, 
 pre-trial ARR, 
 score on the EDSS, 
 duration of MS, 
 the number of patients to whom these characteristics apply, 
 the proportion of women among these patients. 
 
Baseline characteristics were retrieved for the placebo group and across all groups of RMS 
patients. When baseline characteristics across all groups were not available, they were 
calculated by combining data provided for the individual treatment arms [Higgins and Green 
2011, Part 2, Chapter 7.7: Extracting study results and converting to the desired format].  
Where possible, data on RRMS patients were preferred over data on patients with other forms 
of MS. When the mean age at baseline was not given, it was calculated by adding the mean MS 
duration to the mean age at the onset of the disease, if provided. Baseline characteristics of 
patients randomized to treatment arms were preferred over characteristics describing only 
patients who actually received treatment. 
If pre-trial ARR was not specified, but the number of relapses in a certain time period or a non-
annualized relapse rate was, it was calculated in the same manner as the trial ARR (see above). 
If studies presented multiple pre-trial ARRs calculated over different time periods, all were 
extracted. 
For ARRs without a quoted standard error (compare Section 10.2.), errors were derived based 
on a Poisson approximation, assuming a variance equal to the mean value. 
 Data analysis 
For the purpose of all analyses of temporal trends, the year and month of publication was used, 
whereas in figures references were sorted by the year of publication and within it alphabetically, 
spread across the year in question, to allow for clarity. The resulting order is maintained 
throughout this dissertation, and each paper was assigned an identifying number. 
When mean values were not given, available median values were used as a direct estimate 
instead, if they did not require extrapolation. Corresponding IQRs, if not equal to zero, were 
used to estimate SDs, assuming normal distributions. Values obtained in such a manner are 
indicated in the figures. Mean values with SDs had top priority, mean values with SDs estimated 
 
18 
from IQRs second, median values with SDs estimated from IQRs third priority, followed by 
solitary mean values and lastly solitary median values. 
2.4.1 Outcome data 
The natural logarithms of the trial ARR of placebo groups were modeled by Gaussian linear 
regression over time, weighted by the inverse standard error squared. For the means 95% CIs 
were calculated. 
Unweighted linear regressions over time were calculated for: 
 
 The duration of placebo-controlled follow-up, 
 the number of patient years considered for the calculation of trial ARRs, 
 the dispersion of trial ARRs in placebo groups, utilizing only variances based on stated data. 
2.4.2 Oxford Quality Scale 
The score on the Oxford Quality Scale was analyzed by unweighted linear regressions over 
time. 
2.4.3 Study design features 
Unweighted linear regressions over time were calculated for: 
 
 The number of eligibility criteria, 
 the number of words describing the eligibility criteria, 
 the ratio of words per criterion, 
 the number of characters describing the eligibility criteria 
 the ratio of characters per criterion, 
 the minimum pre-trial ARR for inclusion, 
 the number of years considered for the calculation of pre-trial ARRs, 
 the minimum age for inclusion, 
 the maximum age for inclusion, 
 the minimum score on the EDSS for inclusion, 
 the maximum score on the EDSS for inclusion, 
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 the minimum number of days without relapse, 
 the minimum number of days without the use of high-dose steroids, 
 the number of treatment arms, 
 the mean number of patients per treatment arm. 
 
Inclusion criteria were omitted in analyses of individual items, when they appeared in a 
complex context that allowed alternative options to qualify in one measure or mutually 
exclusive options of different measures (For example: Study inclusion required patients to have 
either two relapses in the last two years, or one relapse in the last six months, or two 
Gadolinium-enhancing lesions in the Magnetic Resonance Imaging (MRI) at baseline). They 
were, however, still counted. 
2.4.4 Patient characteristics at baseline 
The natural logarithms of the pre-trial ARR of placebo groups and across all groups were 
modeled by Gaussian linear regression, weighted by the inverse SE squared. For the means, 
95% CIs were calculated. When multiple pre-trial ARRs could be collected, those accounting 
for the longest period were used. 
In all cases of multiple pre-trial ARRs, ARRs were stated for the time period one year before 
baseline and for the time period two years before baseline. From those, the pre-trial ARR of the 
year preceding baseline and of the second preceding year were derived [Higgins and Green 
2011, Part 2, Chapter 7.7: Extracting study results and converting to the desired format]. The 
logarithmic ratios of these ARRs of different pre-trial time periods of equal length were 
investigated via a random-effects meta-analysis with inverse variance weighting. The combined 
estimates are reported along with 95% CIs and p-values testing the null hypothesis of no 
difference between the time intervals. Heterogeneity between studies is estimated and reported 
in terms of the heterogeneity measure I2, which is the ratio of the between-trial variance and the 
total variance, alongside the p-values of the chi-square test of heterogeneity. Forest plots 
illustrating the ratios of the individual studies and the combined effect allow for visual 
comparison of the heterogeneity and provide an overview of the results. 
Linear regressions over time, weighted by the inverse SE squared, taking all values with SEs 
into account, were calculated for the following baseline characteristics of the placebo groups 
and across all groups: 
 
 Age, 
 disease duration, 




2.4.5 Epoch analyses 
As supportive analyses of the most important items, the mean values of four deliberate 
partitions of the 56 trials included in this study were compared, testing for possible trends that 
might have been concealed in the analysis of all studies over time. These analyses are referred 
to as epoch analyses. Recognizable points in trial history were chosen to subdivide the trunk of 
trials: The first cluster of trials comprised all trials up to the end of 1994, the second cluster all 
trials from the beginning of 1995 to the end of 2000, the third cluster all trials from the 
beginning of 2001 to the end of 2009, the fourth cluster all trials from the beginning of 2010 to 
today. The divisors in mind were 1995 as the year of the renowned IFNB trial (study ID #10), 
2001 as the year of the influential Comi trial investigating Glatiramer Acetate (study ID #30) 
and 2010 as the year when large numbers of patients included to phase 3 studies became more 
common. The following items were analyzed in this manner: 
 
 The trial ARR in placebo groups, 
 the duration of placebo-controlled follow-up, 
 scores on the Oxford Quality Scale, 
 the number of eligibility criteria, 
 the number of words describing the eligibility criteria, 
 the number of characters describing the eligibility criteria, 
 the minimum pre-trial ARR for inclusion, 
 the number of years considered for the calculation of pre-trial ARRs, 
 the minimum score on the EDSS for inclusion, 
 the maximum score on the EDSS for inclusion, 
 the minimum number of days without relapse, 
 the minimum number of days without the use of high-dose steroids, 
 the mean age in placebo groups and across all groups at baseline, 
 the mean disease duration in placebo groups and across all groups at baseline, 
 the mean score on the EDSS in placebo groups and across all groups at baseline, 
 the mean pre-trial ARR in placebo groups and across all groups, 




2.4.6 Statistical considerations 
The level of statistical significance was set at α = 0.05. The p-value gives the probability of the 
test statistic reaching the observed or a more extreme value under the null hypothesis, i.e. the 
assumption that there is no correlation between the variable in question and the given data. If 
𝑝 ≤ α, rejection of the null hypothesis is justified for a given probability α of a type I error. 
Statistical computing software (R version 2.14.2, URL: http://www.r-project.org/; Review 
Manager (RevMan) version 5.1, The Nordic Cochrane Centre, The Cochrane Collaboration, 
2011, URL: http://ims.cochrane.org/revman/) was used for all analyses and Figures 6 to 36. 
2.4.6.1 Regression models 
Typically, a regression model consists of an intercept plus the sum of a number of variables 
multiplied by individual coefficients [Kutner et al. 2005]: 
𝑦 = (∑ 𝑎𝑖𝑥𝑖
𝑛
𝑖=1
) + 𝑏 + 𝜀 
In this formula, 𝑦 is the true trial ARR, 𝑛 the number of variables included in the regression 
model, 𝑥𝑖 any of the variables included – with 𝑎𝑖 as the assigned coefficient, 𝑏 the intercept and 
𝜀 the residual error. In linear regression models for example, 𝑛 is set to 1.  
2.4.6.2 Meta-regression of statistically significant temporal trends 
Finally, all statistically significant temporal trends were investigated in a meta-regression 
calculating to what extent they contributed to the temporal trend in trial ARRs. Here a more 
complex regression model was sought. 
When there are 𝑣 number of variables that might be included in the regression, the possible 
number of combinations and consequently the number of regression models is 2𝑣. For example, 
provided that 𝑣 = 10, there would be 210 = 1024 different regression models that needed to 
be compared, in order to find the best one. To do that, use of the Bayesian information criterion 
(BIC) was made. The BIC is a criterion that offers a way to compare different regression models 
and choose the best of them: 
BIC = −2 ∙ ln(𝐿) + 𝑛 ∙ ln (𝑠) 
In this case, 𝑠 the number of studies analyzed, while 𝑛 is the number of variables included in 
the regression model. The Likelihood 𝐿  is a function that calculates how good a fit the 
regression model is, i.e. how likely the regression resembles the given data set it is supposed to 
model. 
The best regression model is the one with the minimal BIC, which is minimized by increasing 
likelihood, but boosted by increasing numbers of included variables, therefore targeting a model 
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that explains as much as possible, yet simultaneously remaining as simple as possible [Kass 
and Raftery 1995, p790]. 
When the final regression model is chosen, the coefficient of determination 𝑅2  allows 
quantifying the percentage to which the model explains the given data. It is calculated through 
the residual sum of squares divided by the total sum of squares [Kutner et al. 2005]: 
𝑅2 ≡  1 −
 ∑ (𝑦𝑘 − 𝑓𝑘)²
𝑠
𝑘=1




In this formula, 𝑦𝑘 is the given data value and 𝑓𝑘 its regression-modeled value, ?̅? is the mean 
of the given data. This way 𝑅2 is bound to be a value between one and zero, with 𝑅2 = 0 
showing no correlation between the regression model and the data set at all, and 𝑅2 = 1 
showing a perfect regression model, which would be able to explain each given value in the 






 Literature search 
A total of 56 randomized, placebo-controlled, double-blind clinical trials was identified, 
including a total of 14,792 patients, of which 5,380 had been randomized to placebo. Table 1 
gives an overview of the studies and their assigned identification numbers. Tabulated 
summaries of the 56 trials are provided in the appendix (see Section 10.2). 
 
Table 1: Studies included in the data analysis 
Study ID No. First authorship 
#1 [Gonsette et al. 1982] 
#2 [Mertin et al. 1982; Mertin et al. 1980] 
#3 [Camenga et al. 1986] 
#4 [Jacobs et al. 1987; Jacobs et al. 1986] 
#5 [Hirsch et al. 1988] 
#6 [Milanese et al. 1988] 
#7 [Goodkin et al. 1991] 
#8 [Bastianello et al. 1994] 
#9 [Durelli et al. 1994] 
#10 [The IFNB Multiple Sclerosis Study Group & the University of British Columbia 
MS/MRI Analysis Group 1995; the IFNB Multiple Sclerosis Study Group 1993] 
#11 [Andersen et al. 1996] 
#12 [Jacobs et al. 1996] 
#13 [Lycke et al. 1996] 
#14 [Fazekas et al. 1997] 
#15 [Millefiorini et al. 1997] 
#16 [Miller et al. 1997] 
#17 [Van Oosten et al. 1997; Van Oosten et al. 1996] 
#18 [Achiron et al. 1998] 
#19 [Johnson et al. 1998; Johnson et al. 1995] 
#20 [Noseworthy et al. 1998] 
#21 [Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in 
Multiple Sclerosis Study Group 1998] 
#22 [Deisenhammer et al. 1999] 
#23 [Lenercept Multiple Sclerosis Study Group & the University of British Columbia 
MS/MRI Analysis Group 1999] 
#24 [Myhr et al. 1999] 
#25 [The Once Weekly Interferon for MS Study Group 1999] 
#26 [Patti et al. 1999] 
#27 [Romine et al. 1999] 
#28 [Tubridy et al. 1999] 
#29 [Brod et al. 2001] 
#30 [Comi et al. 2001] 
#31 [Bech et al. 2002] 
#32 [Lewańska et al. 2002] 
#33 [Miller et al. 2003] 
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Study ID No. First authorship 
#34 [Wroe 2005] 
#35 [Filippi et al. 2006] 
#36 [Kappos et al. 2006] 
#37 [O'Connor et al. 2006] 
#38 [Polman et al. 2006] 
#39 [Broadley et al. 2008] 
#40 [Comi et al. 2008] 
#41 [Fazekas et al. 2008] 
#42 [Garren et al. 2008] 
#43 [Hauser et al. 2008] 
#44 [Kappos et al. 2008] 
#45 [Mostert et al. 2008] 
#46 [Segal et al. 2008] 
#47 [Barkhof et al. 2010] 
#48 [Giovannoni et al. 2010] 
#49 [Kappos et al. 2010] 
#50 [Vollmer et al. 2010] 
#51 [De Stefano et al. 2011; De Stefano et al. 2010] 
#52 [Kappos et al. 2011] 
#53 [O'Connor et al. 2011] 
#54 [Comi et al. 2012] 
#55 [Miller et al. 2012] 





 Outcome data 
3.2.1 Trial ARRs in placebo groups 
As shown in Figure 6, trial ARRs in placebo groups decreased by 4.56% per year (95% CI: 3.24 
– 5.89%). In the time span investigated, this accumulated to a decrease of nearly 1.5 relapses 
per year, starting with a rate of 2.0. This finding was expected, yet its dimension still impressive. 
 
Figure 6: Trial ARR (placebo groups) 
The axis of abscissae represents time, the axis of ordinates the trial ARR in placebo groups. Symbol sizes 
correspond to SEs; the inner gray trend line shows the result of the regression; the outer dashed lines serve as 





3.2.2 Duration of placebo-controlled follow-up 
The duration of placebo-controlled follow-up decreased yearly by 16 days (p-value = 0.006; 
coeff = -15.782 (95% CI: -26.923 – -4.641)) on average, as shown in Figure 7. Given that the 
trials included in the analyses were either phase II or phase III (phase II studies usually last 
from 6 – 9 months, phase III studies usually 1 - 2 years), and less than half of the trials made 
specifications to their phase, the visible decrease is likely to reflect both the emergence of more 
phase II studies in the later years, as well as a possible tendency toward shorter phase III studies. 
 
Figure 7: Duration of placebo-controlled follow-up in days 
The axis of abscissae represents time, the axis of ordinates the duration of placebo-controlled follow-up. The red 





3.2.3 Number of patient years considered for the calculation of trial 
ARRs 
Changes in the number of patient years considered for the calculation of trial ARRs in placebo 
groups did not meet statistical significance (p-value = 0.051; coeff = 8.58 (95% CI: 0.15 – 
17.01)). Since statistical significance was missed by a close 0.001, the upward trend indicated 
by the red line in Figure 8 may still be worth a glimpse. 
 
Figure 8: Number of patient years considered for the calculation of trial ARRs (placebo groups) 
The axis of abscissae represents time, the axis of ordinates the number of patient years considered for the 





3.2.4 Dispersion of trial ARRs in placebo groups 
Changes in the dispersion of trial ARRs, i.e. the variance divided by the mean value, did not 
reach statistical significance (p-value = 0.314; coeff = 0.03 (95% CI: -0.027 – 0.086)), as shown 
in Figure 9. The discussion will delve into this notion. 
 
Figure 9: Dispersion of trial ARR (placebo groups) 
The axis of abscissae represents time, the axis of ordinates the dispersion of trial ARRs. The red trend line shows 




 Oxford Quality Scale 
Scores on the OQS increased by half a point in 18 years (p-value = 0.022; coeff = 0.028 (95% 
CI: 0.004 – 0.051)) on average, despite the outlier in 2011 (study ID #51). As can be seen in 
Figure 10, most studies scored 4 or 5 points on the scale, which may be considered as rather 
good results. 
 
Figure 10: Scores on the Oxford Quality Scale 
The axis of abscissae represents time, the axis of ordinates scores on the OQS. The red trend line shows the 





 Study design features  
3.4.1 Data on eligibility criteria 
Number of eligibility criteria 
As shown in Figure 11, the number of eligibility criteria increased on average by three criteria 
every four years (p<0.001; coeff = 0.771 (95% CI: 0.392 – 1.151)). This may to a part reflect 
the growing understanding of the investigated interventions, a relation to the increasing quality 
in reporting is nonetheless likely to play a role. 
 
Figure 11: Number of eligibility criteria 
The axis of abscissae represents time, the axis of ordinates the number of eligibility criteria. The red trend line 






Number of words describing the eligibility criteria 
The number of words describing the eligibility criteria increased on average by 20 words every 
three years (p<0.001; coeff = 6.651 (95% CI: 3.372 – 9.93)), as visible in Figure 12. Given the 
increasing number of eligibility criteria, this was to be expected. 
 
Figure 12: Number of words describing eligibility criteria 
The axis of abscissae represents time, the axis of ordinates the number of words describing the eligibility criteria. 






Words per eligibility criterion 
The average ratio of words per eligibility criterion decreased by 1 word every 9 eligibility 
criteria (p-value = 0.039; coeff = -0.112 (95% CI: -0.215 – -0.008)), as shown in Figure 13. 
Plain listings of eligibility criteria are common and additional criteria oftentimes result in no 
more than one additional word, so the decrease was not unexpected. 
 
Figure 13: Ratio of words per eligibility criterion 
The axis of abscissae represents time, the axis of ordinates the ratio of words per eligibility criterion. The red 






Number of characters describing the eligibility criteria 
As shown in Figure 14, the number of characters describing the eligibility criteria increased on 
average by 40 characters every year (p<0.001; coeff = 39.638 (95% CI: 20.109 – 59.168)). 
Given the increasing number of eligibility criteria, this was to be expected. 
 
 
Figure 14: Number of characters describing eligibility criteria 
The axis of abscissae represents time, the axis of ordinates the number of characters describing the eligibility 






Characters per eligibility criterion 
As shown in Figure 15, changes in the average ratio of characters per eligibility criterion did 
not reach statistical significance (p-value = 0.078; coeff = -0.523 (95% CI: -1.093 – 0.047)). 
Analogous to the ratio of words per eligibility criterion, this was expected. 
 
Figure 15: Ratio of characters per eligibility criterion 
The axis of abscissae represents time, the axis of ordinates the ratio of characters per eligibility criterion. The red 





3.4.1.1 Pre-trial ARR 
Minimum pre-trial ARR for inclusion 
Changes in the minimum pre-trial ARR for inclusion did not reach statistical significance (p-
value = 0.582; coeff = 0.003 (95% CI: -0.008 – 0.013)). As easily seen in Figure 16, the 
minimum pre-trial ARR for inclusion remained roughly at one relapse per year. 
 
 
Figure 16: Minimum pre-trial ARR for inclusion 
The axis of abscissae represents time, the axis of ordinates the minimum pre-trial ARR for inclusion to the study. 






Number of years considered for the calculation of pre-trial ARR 
The time period considered for the calculation of pre-trial ARR decreased by 18 days every 
year (p-value=<0.001; coeff = -0.049 (95% CI: -0.071 – -0.027)) on average, as shown in Figure 
17. This was a rather remarkable finding; at the beginning of the investigated time period, the 
occurrence of relapses of recruit patients tested for eligibility was mostly inquired for the last 
two or three years before commencement of the trial, after 2005 inquiries for only one year 
became customary. 
 
Figure 17: Number of years considered for the calculation of pre-trial ARR 
The axis of abscissae represents time, the axis of ordinates the years considered when calculating the pre-trial 





3.4.1.2 Eligible age 
As Figure 18 shows, the minimum age for inclusion increased by one year every 29 years (p-
value = 0.031; coeff = 0.035 (95% CI: 0.004 – 0.066)), while the maximum age for inclusion 
increased by one year every three years (p-value = 0.005; coeff = 0.364 (95% CI: 0.124 – 
0.603)). With increasing limits of eligible age, an increase in baseline age becomes more likely. 
 
Figure 18: Eligible age 
The axis of abscissae represents time, the axis of ordinates the age of patients. Bars depict the range of eligible 





3.4.1.3 Eligible scores on the EDSS 
Neither the changes of the minimum (p-value = 0.051; coeff = -0.028 (95% CI: -0.056 – 0)) nor 
the maximum eligible score on the EDSS (p-value = 0.986; coeff < -0.001 (95% CI: -0.036 – 
0.035)) were statistically significant. Figure 19 provides an overview of the margins of eligible 
EDSS scores over the years. 
 
 
Figure 19: Eligible scores on the EDSS 
The axis of abscissae represents time, the axis of ordinates scores on the EDSS. Bars depict the range of eligible 





3.4.1.4 Minimum number of days without relapse 
Changes in the minimum number of days before baseline without relapse did not reach 
statistical significance (p-value = 0.247; coeff = -0.623 (95% CI: -1.701 – 0.456)). Yet as visible 
in Figure 20, there seem to be some conventions as to how long patients must not have relapsed 
before baseline; the period of one month was most frequently stated. 
 
Figure 20: Minimum number of days without relapse 
The axis of abscissae represents time, the axis of ordinates the minimum number of days without relapse. The 





3.4.1.5 Minimum number of days without the use of high-dose 
steroids 
Changes in the minimum number of days before baseline without the use of high-dose steroids 
did not reach statistical significance (p-value = 0.059; coeff = -0.991 (95% CI: -2.019 – 0.038)). 
Similar to the minimum number of days without relapse (see Section 3.4.1.4), Figure 21 seems 




Figure 21: Minimum number of days without the use of high-dose steroids 
The axis of abscissae represents time, the axis of ordinates the number of days without the use of high-dose 





3.4.2 Additional study design features 
Number of treatment arms 
As shown in Figure 22, the average number of treatment arms increased by one treatment every 
21 years (p<0.001; coeff = 0.048 (95% CI: 0.028 – 0.068)). The least number of treatment arms 
was two, as control groups were mandatory for the inclusion of trials to this study. As can be 
gathered from the tabulated summaries in the appendix, the additional treatment arms 
comprised only different dosages of the same intervention. 
 
Figure 22: Number of treatment arms 
The axis of abscissae represents time, the axis of ordinates the number of treatment arms. The red trend line 






Mean number of patients per treatment arm 
The number of patients per treatment arm increased by 7 patients per year (p-value = 0.003; 
coeff = 7.028 (95% CI: 2.532 – 11.524)) on average. As becomes obvious in Figure 23, this 
finding is caused to a major part by six studies published after 2005. 
 
Figure 23: Number of patients per treatment arm 
The axis of abscissae represents time, the axis of ordinates the number of patients per treatment arm. The red 





 Patient characteristics at baseline 
3.5.1 Pre-trial ARRs 
Placebo groups 
Pre-trial ARRs in placebo groups decreased by 2.15% per year (95% CI: 1.49 – 2.82%), as 
shown in Figure 24. This approximates almost half of the analogous trend in trial ARRs. A 
direct comparison of both trends is part of the discussion. 
 
Figure 24: Pre-trial ARRs (placebo groups) 
The axis of abscissae represents time, the axis of ordinates the pre-trial ARR. Symbol sizes correspond to SEs; 
the inner gray trend line shows the result of the regression; the outer dashed lines serve as borders to the 95% CI 
highlighted in light gray. 
 
All groups 
Pre-trial ARRs across all groups decreased by 1.98% per year (95% CI: 1.35 – 2.62%), as shown 





Figure 25: Pre-trial ARRs (all groups) 
The axis of abscissae represents time, the axis of ordinates the pre-trial ARR. Symbol sizes correspond to SEs; 
the inner gray trend line shows the result of the regression; the outer dashed lines serve as borders to the 95% CI 
highlighted in light gray. 
 
 
Multiple pre-trial ARRs of placebo groups 
As shown in Table 2, six trials provided multiple pre-trial ARRs with corresponding SDs:  
 
Table 2: Studies providing multiple pre-trial ARRs 
 
Study 
1st preceding year 2nd preceding year   Total 
Mean (SD) Mean (SD) Mean (SD) n 
Filippi 2006 1.5 (0.8) 0.7 (0.894) 1.1 (0.6) 548 
Kappos 2010 1.5 (0.8) 0.7 (0.894) 1.1 (0.6) 418 
O’Connor 2011 1.4 (0.7) 0.8 (0.714) 1.1 (0.5) 363 
Miller 2012 1.7 (0.7) 1.0 (0.686) 1.35 (0.49) 99 
Saida 2012 1.7 (1.6) 1.1 (2.538) 1.4 (1.5) 57 
Comi 2012 1.3 (0.7) 0.6 (0.714) 0.95 (0.5) 363 
 
ARRs of the year directly preceding baseline (including months -12 to -1) nearly doubled 
compared to those of the second preceding year before baseline (including months -24 to -13), 
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as shown in Figure 26 and Table 3. This stands in contrast to the notion of constant ARRs. A 
closer look at this finding is provided in the discussion. 
 












Mean age at baseline in placebo groups increased by one year every five years (p<0.001; coeff 
= 0.199 (95% CI: 0.098 – 0.299)) on average, as shown in Figure 27. This accumulates to an 
increase of six years in the investigated time span. 
 
Figure 27: Mean age at baseline (placebo groups) 
The axis of abscissae represents time, the axis of ordinates the age of patients. The red trend line shows the 
result of the linear regression; gray symbols indicate values omitted due to lacking SEs; whiskers indicate the 







As shown in Figure 28, mean age at baseline across all groups increased by one year every five 
years (p<0.001; coeff = 0.2 (95% CI: 0.111 – 0.288)) on average, very similar to the finding in 
the placebo patients. A closer look at this change in the composition of trial populations will be 
part of the discussion. 
 
Figure 28: Mean age at baseline (all groups) 
The axis of abscissae represents time, the axis of ordinates the age of patients. The red trend line shows the 
result of the linear regression; gray symbols indicate values omitted due to lacking SEs; whiskers indicate the 





3.5.3 Disease duration 
Placebo groups 
Mean disease duration in placebo groups increased one year every eight years (p-value = 0.048; 
coeff = 0.122 (95% CI: 0.001 – 0.243)) on average, as shown in Figure 29. The average patient’s 
history of MS before commencement of the trial was therefore prolonged by nearly four years 
in the time span investigated. 
 
Figure 29: Mean disease duration at baseline (placebo groups) 
The axis of abscissae represents time, the axis of ordinates the duration of disease. The red trend line shows the 
result of the linear regression; gray symbols indicate values omitted due to lacking SEs; whiskers indicate the 







As shown in Figure 30, the mean disease duration across all groups increased one year every 
eight years (p-value = 0.042; coeff = 0.119 (95% CI: 0.005 – 0.233)) on average. The similarity 
to the finding in the placebo groups was expected. 
 
Figure 30: Mean disease duration at baseline (all groups) 
The axis of abscissae represents time, the axis of ordinates the duration of disease. The red trend line shows the 
result of the linear regression; gray symbols indicate values omitted due to lacking SEs; whiskers indicate the 





3.5.4 Scores on the EDSS 
Placebo groups 
Changes in mean scores on the EDSS in placebo groups did not reach statistical significance 
(p-value = 0.289; coeff = 0.011 (95% CI: -0.01 – 0.031)), as visible in Figure 31. The red trend 
line in Figure 31 - although insignificant - may appear counterintuitive, however, a look the 
results of the corresponding epoch analysis and the frames of standard errors especially serves 
as an explanation for this phenomenon. 
 
Figure 31: Mean scores on the EDSS (placebo groups) 
The axis of abscissae represents time, the axis of ordinates scores on the EDSS. The red trend line shows the 
result of the linear regression; gray symbols indicate values omitted due to lacking SEs; whiskers indicate the 







Changes in mean scores on the EDSS across all groups did not reach statistical significance (p-
value = 0.554; coeff = 0.007 (95% CI: -0.017 – 0.03)), as visible in Figure 32. The similarity to 
the finding in the placebo groups was expected. 
 
 
Figure 32: Mean scores on the EDSS (all groups) 
The axis of abscissae represents time, the axis of ordinates scores on the EDSS. The red trend line shows the 
result of the linear regression; gray symbols indicate values omitted due to lacking SEs; whiskers indicate the 





3.5.5 Gender distribution 
Placebo groups 
Changes in the proportion of women among placebo patients at baseline did not reach statistical 
significance (p-value = 0.337; coeff = -0.001 (95% CI: -0.004 – 0.001)), as depicted in Figure 
33. This finding was rather unexpected; the discussion will delve into this point. 
 
Figure 33: Changes in the fraction of female patients (placebo groups) 
The axis of abscissae represents time, the axis of ordinates the fraction of female patients. The red trend line 
shows the result of the linear regression; whiskers indicate the 95% CI; symbol size correlates to the square root 







Changes in the proportion of women among patients across all groups at baseline did not reach 
statistical significance (p-value = 0.593; coeff = -0.001 (95% CI: -0.002 – 0.001)), as depicted 
in Figure 34. The similarity to the finding in the placebo groups was expected. 
 
Figure 34: Changes in the fraction of female patients (all groups) 
The axis of abscissae represents time, the axis of ordinates the fraction of female patients. The red trend line 
shows the result of the linear regression; whiskers indicate the 95% CI; symbol size correlates to the square root 
of sample size (compare 10.2.). 
 
 Epoch analyses 
Table 4 gives an overview of the results of the epoch analyses. Mean values of the different 
clusters are stated with corresponding SEs and were tested for equality across epochs (p-values). 




Table 4: Results of the epoch analyses 
Item p -value 
 1982 –  
1994 
1995 –  
2000 




trial ARR in placebo groups <0.001 
mean 1.155 1.078 0.767 0.412 
SE 0.373 0.071 0.116 0.032 
duration of placebo-controlled 
follow-up (in days) 
0.004 
mean 557.882 657.57 275.594 405.288 
SE 104.147 71.679 73.643 98.803 
scores on the OQS 0.291 
mean 4 4.421 4.444 4.6 
SE 0.233 0.161 0.165 0.221 
number of eligibility criteria 0.004 
mean 8.889 13.79 18.889 27.3 
SE 3.785 2.605 2.677 3.591 
number of words describing the 
eligibility criteria 
0.002 
mean 81.556 125.9 158.111 253.4 
SE 32.101 22.094 22.699 30.454 
number of characters describing the 
eligibility criteria 
0.002 
mean 459.111 711.526 894.333 1486.4 
SE 190.731 131.27 134.867 180.944 
minimum pre-trial ARR for inclusion 0.824 
mean 1 1 0.964 1.074 
SE 0.103 0.064 0.073 0.09 
number of years considered for 
the calculation of pre-trial ARRs 
0.008 
mean 2.214 1.972 1.417 1.5 
SE 0.204 0.127 0.156 0.242 
minimal score on the EDSS for 
inclusion 
0.107 
mean 0.667 0.632 0.167 0.1 
SE 0.293 0.164 0.169 0.227 
maximal score on the EDSS for 
inclusion 
0.269 
mean 6 5.237 5.472 5.7 
SE 0.364 0.205 0.21 0.282 
minimum number of days without 
relapse 
0.342 
mean 60.873 38.219 39.211 34.333 
SE 12.493 5.587 4.9 7.213 
minimum number of days without 
the use of high-dose steroids 
0.02 
mean 68.484 35.473 38.356 31.571 
SE 9.469 5.061 5.252 7.158 
mean age in placebo groups at 
baseline 
0.004 
mean 32.031 35.382 36.532 37.977 
SE 2.267 0.622 0.5 0.459 
mean age across all groups at 
baseline 
<0.001 
mean 31.553 35.33 36.329 37.836 
SE 1.961 0.547 0.408 0.373 
mean disease duration in placebo 
groups at baseline 
0.007 
mean 5.836 5.154 5.453 8.146 
SE 1.733 0.608 0.635 0.609 
mean disease duration across all 
groups at baseline 
0.01 
mean 5.779 5.7 5.943 8.287 
SE 1.717 0.596 0.579 0.527 
mean score on the EDSS in 
placebo groups at baseline 
0.004 
mean 3.671 2.474 2.347 2.725 
SE 0.475 0.098 0.091 0.076 
mean score on the EDSS across 
all groups at baseline 
0.003 
mean 3.619 2.562 2.309 2.722 
SE 0.497 0.112 0.086 0.077 
mean pre-trial ARR in placebo 
groups 
0.001 
mean 1.571 1.466 1.202 1.058 
SE 0.255 0.077 0.067 0.051 
mean pre-trial ARR across all 
groups 
<0.001 
mean 1.569 1.424 1.219 1.067 
SE 0.218 0.067 0.056 0.042 
gender distribution in placebo 
groups 
0.34    
mean 0.657 0.721 0.7 0.692 
SE 0.048 0.015 0.014 0.012 
gender distribution across all 
groups 
0.031 
mean 0.635 0.71 0.718 0.692 




 Meta-regression of statistically significant temporal trends 
The temporal trend line for the trial ARR, as shown in Figure 6, explains about 46% of the 
variation observed in trial ARRs over the years (Figure 35, left column). To gain insights into 
the drivers of this trend, meta-regression incorporating changes in patient populations and trial 
characteristics was utilized. After taking all possible combinations of variables into 
consideration, the final model included pre-trial ARR, the number of years considered for the 
calculation of pre-trial ARR, duration of placebo-controlled follow-up and mean MS duration 
at baseline, as shown in Figure 35. The year of publication was added for comparison with the 
simple model including the time trend only. In the resulting model explaining about 69% of the 
variation in trial ARR, the temporal trend becomes insignificant with major contributors being 
pre-trial ARR, the number of years used to calculate pre-trial ARR, study duration, and MS 
duration (Figure 35, right column). 
 
 
Figure 35: Meta-regression explaining variation of trial ARR 
The left column shows the percentage of variation in trial ARRs that can be explained by the temporal trend line 
shown in Figure 6; the right column shows the percentage of variation in trial ARRs that can be explained by the 





The data which this dissertation was based on were extracted from published journals, thus 
bearing editorial restrictions, as journals can only afford for the most substantial data to be 
published as opposed to the entire data. Hence, in most cases only aggregated data was 
accessible, not individual patient data, which would have been of higher statistical value. Still, 
Quality and quantity of reported data varied widely, as depicted in the increase in scores on the 
OQS (see Section 3.3) and in sample size. This may reflect higher trial quality or better 
reporting in more recent trials, consistent with the findings of Signori [Signori et al. 2012].  
Results of the epoch analyses have to be interpreted with caution, since the clusters were defined 
arbitrarily. In addition, mean values of the first cluster in particular are based on small samples, 
making aberrancies in this epoch more likely. One example of this is the detected drop in the 
minimum steroid-free time before baseline since 1995, based only on four trials in the first 
cluster.  
Nonetheless, the available data proved conclusive with respect to the aim of this dissertation, 
namely describing the downward trend in trial ARRs in placebo patients and identifying 
possible causal factors. 
In the 56 RCTs analyzed in this dissertation, the trial ARRs in placebo patients decreased by 
4.56% per year (95% CI: 3.24 – 5.89%). This is consistent with previous findings by Inusah et 
al. and Nicholas et al., who conducted their reviews on different, though overlapping sets of 
trials: Nicholas et al. found trial ARRs to be decreasing at 6.2% per year (95% CI: 4.2 – 8.1%) 
in a set of 26 RCTs [Nicholas et al. 2011a], Inusah stated absolute data and found a yearly 
reduction of 0.036 (95% CI: 0.02 – 0.052) relapses in 32 RCTs [Inusah et al. 2010]. 
Also, pre-trial ARRs were found to be decreasing by 2.15% per year (95% CI: 1.49 – 2.82%). 
The causal relationship between pre-trial and trial ARR is obvious: If patients have a lower 
ARR at the start of a study, lower outcomes (= trial ARRs) are to be expected. Figure 36 
captures the development of both rates over time. 
Decreasing pre-trial ARRs may in turn be related to the increasing age and duration of MS of 
patients in the trials. 
Tremlett et al. found a reduction in ARRs by 17% for every 5 years of MS duration [Tremlett 
et al. 2008].  The increase in MS duration by 3.6 years, as observed in this study (see Section 
3.5.3), could constitute a 13% decrease in ARRs. Similarly, patients at baseline were on average 
approximately six years older at the end of the observation period than at its beginning (see 
Section 3.5.2) – this notion is consistent with the accordingly increasing limits of eligible age 
(see Section 3.4.1.2). A correlation of higher age with lower trial ARR could be shown in a 
meta-analysis of 13 patient cohorts [Stellmann et al. 2012]. Considering this, in an older trial 






Figure 36: Pre-trial ARR and trial ARR in placebo groups 
The axis of abscissae represents time, the axis of ordinates the ARRs of placebo patients. Symbol sizes 
correspond to SEs; inner trend lines show the results of regressions; outer dashed lines serve as borders to the 
95% CIs highlighted in light gray. 
 
 
Older patients in newer trials with longer disease duration but relatively stable EDSS scores 
(after an early drop, especially in trials since 1995; see Section 3.6) may even have less severe 
disease courses than the younger patients in older trials. The increasing availability of 
increasingly effective disease modifying treatments could be a likely driver in this, as suggested 
by Inusah [Inusah et al. 2010]. 
Another factor contributing to the decrease in trial ARRs is the reduced time period over which 
pre-trial ARRs had been calculated: this decreased on average by 1.5 years over the past three 
decades (see Section 3.4.1.1). Using shorter periods of time over which pre-trial ARRs are 
calculated, might thereby allow trials to include patients who, if pre-trial ARR was assessed 
over a longer time span, might not have been eligible for trial inclusion. In fact, this effect can 
be witnessed in two of the trials that provided multiple pre-trial ARRs (study IDs #36 and #54): 
Both trials presented average pre-trial ARRs for the two-year period before baseline that would 
not have been eligible for inclusion, but were included for their pre-trial ARRs assessed for the 
one-year period before baseline. 
The shortening of the time period considered for the estimation of the pre-trial ARR could be a 
principal factor driving the regression to the mean effect, which has previously been described 
by Martínez-Yélamos [Martínez-Yélamos et al. 2006] and Nicholas [Nicholas et al. 2012] and 
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is very evident in the latest publications on the AFFIRM and the TOP studies [Kappos et al. 
2013].  
The notion that patients are recruited into a study shortly after a flare up of disease activity is 
supported by the finding that the meta-analysis of multiple pre-trial ARRs of the same patients 
in the second preceding year before baseline is almost half of the ARR in the year directly 
before baseline (see Section 3.5.1). 
Since the relative incidence of MS in women compared to men has risen from 2:1 to 4:1 over 
recent years [Koch-Henriksen and Sørensen 2010] and a positive correlation between trial ARR 
and female sex was shown by Held [Held et al. 2005], the lack of a temporal trend over the 30 
year observation period in the gender ratio (see Section 3.5.5) was unexpected, as it would have 
served as one explanation for the phenomenon in question.  The epoch analysis (see Section 
3.6) even indicates a decrease of female patients across all groups since 1995, although this 
militates against the gender ratio playing a role in the downward trend in trial ARRs.  
While growing numbers of eligibility criteria reflect the increasing understanding of the 
complexity of possible influences on outcome variables such as the trial ARR, early trials with 
fewer eligibility criteria might have been more susceptible to such influences than modern ones.  
Similarly, ever changing definitions of MS and relapses, as well as varying forms of report, 
confirmation and treatment in case of relapses undoubtedly play a role, as has been suggested 
by Inusah [Inusah et al. 2010]. 
To find indications of not only higher quantity, but also higher complexity in eligibility criteria, 
analyses of words and characters per criterion were carried out, but did not demonstrate signs 
of increasing complexity. 
Also, the growing numbers of eligibility criteria (see Section 3.4.1) did not seem to have an 
impact on the heterogeneity of the patients, since no incremental underdispersion (a ratio of 
variance to the mean below 1) in trial ARRs was detectable (see Section 3.2.4), which would 
have been a sign of increasing homogeneity of placebo groups. 
As secondary findings, the average number of treatment arms as well as the average number of 
patients in treatment arms increased (see Section 3.4.2) over time.  
The duration of placebo-controlled follow-up decreased over time – although this trend is likely 
caused by the inclusion of both phase II and phase III trials in the analysis, the former being 
relatively short as a matter of principle [European Medicines Agency 1998] and should be 
interpreted with caution. 
In the essential meta-regression (see Section 3.7) the temporal trend line became relatively 
insignificant in explaining the variation in trial ARRs, when the pre-trial ARR, the number of 
years considered for the calculation of pre-trial ARR, the duration of placebo-controlled follow-
up and the mean MS duration at baseline were  included in the calculation. This combination 
of variables was able to explain as much as 69% of the variation in trial ARRs, the most 




Future comparisons of therapies that have been used in trials conducted at different points in 
time should consider the covariates described above in their interpretation of potential 






Recent studies have shown a decrease in annualized relapse rates (ARRs) in placebo groups of 
randomized controlled trials (RCTs) in relapsing multiple sclerosis (RMS). This dissertation 
aimed to describe this trend in a different set of RCTs and to investigate whether patient baseline 
characteristics, eligibility criteria and other study design features could explain this 
phenomenon. 
A literature search of randomized, placebo-controlled trials in RMS offering data on relapses 
in placebo groups identified 56 suitable trials. Data on eligibility criteria and baseline 
characteristics were extracted and tested for significant trends over time.  
Several temporal trends were identified: The number of years considered for the calculation of 
pre-trial ARR as well as pre-trial ARRs themselves decreased, as did the duration of placebo-
controlled follow-up. Pre-trial ARRs of the first and second preceding year before baseline 
showed major inconsistencies. Limits of eligible age as well as mean age increased, as did the 
mean disease duration, the number of eligibility criteria and the number of words and characters 
describing them, scores on the OQS, the number of treatment arms and the average number of 
patients per treatment arm.  
A meta-regression was conducted to estimate the contribution of these temporal trends to the 
decrease of trial ARRs over time. In the final meta-regression modeling of the trial placebo 
ARR, the date of publication was found to be insignificant in explaining the variation in trial 
placebo ARR, whereas pre-trial ARR, the number of years used to calculate pre-trial ARR, 
disease duration and the duration of follow-up became major contributors. 
In conclusion, the decline in trial ARRs most likely results from decreasing pre-trial ARRs and 
a shorter time period over which these were calculated. Increasing duration of illness may also 
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 Tabulated summaries of analyzed trials 
In the following, Definition of MS corresponds to the stated publication providing the criteria 
for the diagnosis of multiple sclerosis. If in any category no data was available, this was 
indicated with a dash. 
 
study ID #1 




Title Modulation of immunity in multiple sclerosis: a double-blind levamisole-placebo controlled 
study in 85 patients 
Authors Gonsette RE, Demonty L, Delmotte P, Decree J, De Cock W, Verhaeghen H, Symoens J 
Date of publication 1982 Journal / 
Reference 
J Neurol 228 (1): 65-72 
Score on the OQS 3 





Placebo; 150 mg/d Levamisole, then 150 mg/w Levamisole 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.23 Number of patients 
considered for calculation 
of trial ARR 
13 





Age 16+ Score on the EDSS - 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR - Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 2 Words / characters describing the 
eligibility criteria 
18 / 86 
Eligible courses of MS RRMS + PRMS + progressive MS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) - Number of patients (females) - 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 




study ID #2 




Title Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: 
final report 
Authors Mertin J, Rudge P, Kremer M, Healey MJ, Knight SC, Compston A, Batchelor JR, 
Thompson EJ, Halliday AM, Denman M, Medawar PB 
Date of publication Aug 1982 Journal / 
Reference 
Lancet 2 (8294): 351-4 
Score on the OQS 3 





Placebo; 3 mg/kg/d Azathioprine 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.018 Number of patients 
considered for calculation 
of trial ARR 
22 





Age 15 – 45 Score on the EDSS 0 – 5 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
3 
Number of eligibility criteria 4 Words / characters describing the 
eligibility criteria 
62 / 292 
Eligible courses of MS Relapsing MS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 22 Number of patients (females) 43 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1 Mean pre-trial ARR (SD) 1 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 




study ID #3 




Title Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis 
Authors Camenga DL, Johnson KP, Alter M, Engelhardt CD, Fishman PS, Greenstein JI, Haley AS, 
Hirsch RL, Kleiner JE, Kofie VY, et al. 
Date of publication Dec 1986 Journal / 
Reference 
Arch Neurol 43 (12): 1239-46 
Score on the OQS 4 





Placebo; 6 MIU/w IFN-alpha-2 
(1:1) 
Trial ARR of the 
placebo group (SD) 
0.8 Number of patients 
considered for calculation 
of trial ARR 
50 







Age 20 – 50 Score on the EDSS 0 – 6.5 
Relapse-free time before baseline - Steroid-free time before baseline 2 months 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 14 Words / characters describing the 
eligibility criteria 
85 / 488 
Eligible courses of MS RRMS + PRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 50 (32) Number of patients (females) 98 (58) 
Mean age (SD) in years 29.4 Mean age (SD) in years 28.073 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 3.1 Mean MS duration (SD) in years 3.492 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.65 Mean pre-trial ARR (SD) 1.699 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.9 Mean score on the EDSS (SD) 1.304 





study ID #4 




Title Intrathecally Administered Natural Human Fibroblast Interferon Reduces Exacerbations of 
Multiple Sclerosis 
Authors Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, Josefowicz R, Cuetter A, 
Husain F, Smith WA, Ekes R, O’Malley JA 
Date of publication Jun 1987 Journal / 
Reference 
Arch Neurol 44 (6): 589-95 
Score on the OQS 5 
Definition of MS McDonald 1975;  





Placebo; 9 MIRU IFN-beta intrathecally 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.48 Number of patients 
considered for calculation 
of trial ARR 
35 





Age - Score on the EDSS - 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR - Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 1 Words / characters describing the 
eligibility criteria 
21 / 126 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 35 (25) Number of patients (females) 69 (48) 
Mean age (SD) in years 33 (7.2) Mean age (SD) in years 32.162 (6.821) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 6.1 Mean MS duration (SD) in years 5.755 (3.739) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 4.3 (2.3) Mean score on the EDSS (SD) 4.251 (2.284) 





study ID #5 




Title The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple 
sclerosis patients: immunological and clinical findings 
Authors Hirsch RL, Johnson KP, Camenga DL 
Date of publication Apr 1988 Journal / 
Reference 
Int J Neurosci 39 (3-4): 189-96 
Score on the OQS 3 







Trial ARR of the 
placebo group (SD) 
0.775 Number of patients 
considered for calculation 
of trial ARR 
50 





Age - Score on the EDSS - 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 2 Words / characters describing the 
eligibility criteria 
28 / 156 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 50 Number of patients (females) 98 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.65 Mean pre-trial ARR (SD) 1.7 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #6 




Title Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. 
Preliminary results 
Authors Milanese C, La Mantia L, Salmaggi A, Campi A, Bortolami C, Tajoli L, Nespolo A, Corridori 
F 
Date of publication Feb 1988 Journal / 
Reference 
Ital J Neurol Sci 9 (1): 53-7 
Score on the OQS 5 





Placebo; 2 – 2.5 mg/kg/d Azathioprine 
(1:1) 
Trial ARR of the 
placebo group (SD) 
0.92 Number of patients 
considered for calculation 
of trial ARR 
7 





Age - Score on the EDSS 0 – 7 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 0.667 Time considered for calculation of 
pre-trial ARR in years 
3 
Number of eligibility criteria 7 Words / characters describing the 
eligibility criteria 
120 / 713 
Eligible courses of MS RRMS + progressive MS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 7 Number of patients (females) 13 
Mean age (SD) in years 34.1 Mean age (SD) in years 33.639 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 7 Mean MS duration (SD) in years 7 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.43 Mean score on the EDSS (SD) 2.31 





study ID #7 




Title The efficacy of azathioprine in relapsing-remitting multiple sclerosis 
Authors Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW 
Date of publication Jan 1991 Journal / 
Reference 
Neurology 41 (1): 20-5 
Score on the OQS 5 





Placebo; 3 mg/kg Azathioprine 
(1:1) 
Trial ARR of the 
placebo group (SD) 
0.94 (0.847) Number of patients 
considered for calculation 
of trial ARR 
25 





Age 18 – 65 Score on the EDSS 2 – 6.5 
Relapse-free time before baseline 1 month Steroid-free time before baseline 1 month 
Minimum pre-trial ARR 1.333 Time considered for calculation of 
pre-trial ARR in years 
1.5 
Number of eligibility criteria 14 Words / characters describing the 
eligibility criteria 
169 / 925 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 25 (17) Number of patients (females) 54 (36) 
Mean age (SD) in years 36.28 Mean age (SD) in years 35.979 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 6.24 (8.34) Mean MS duration (SD) in years 6.278 (7.076) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.547 (0.42) Mean pre-trial ARR (SD) 1.554 (0.389) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.72 (1.6) Mean score on the EDSS (SD) 3.43 (1.408) 





study ID #8 




Title A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year  
Authors Bastianello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, Gasperini C, 
Bozzao A, Gallucci M, Andreula C, et al. 
Date of publication Aug 1994 Journal / 
Reference 
Can J Neurol ScI 21 (3): 266-70 
Score on the OQS 4 





Placebo; 8 mg/m²/month Mitoxantrone 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.67 (1.2) Number of patients 
considered for calculation 
of trial ARR 
12 





Age 18 – 45 Score on the EDSS 2 – 5 
Relapse-free time before baseline - Steroid-free time before baseline 3 months 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 22 Words / characters describing the 
eligibility criteria 
140 / 842 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 12 (7) Number of patients (females) 25 (15) 
Mean age (SD) in years 28.5 (6.5) Mean age (SD) in years 29.228 (5.779) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 5 (2.7) Mean MS duration (SD) in years 5.104 (2.496) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.65 (0.6) Mean pre-trial ARR (SD) 1.52 (0.601) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.5 (1) Mean score on the EDSS (SD) 3.604 (0.845) 





study ID #9 




Title Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI 
signs of disease activity, and lymphocyte interferon gamma production in relapsing-
remitting multiple sclerosis 
Authors Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai 
S, Geuna M, et al. 
Date of publication Mar 1994 Journal / 
Reference 
Neurology 44 (3 Pt 1): 406-13 
Score on the OQS 4 





Placebo; 9 MIU/2d rIFNalpha-2a i.m. 
(2:3) 
Trial ARR of the 
placebo group (SD) 
2 (1.527) Number of patients 
considered for calculation 
of trial ARR 
8 
Primary outcome Relapse-related / MRI-related / 






Age - Score on the EDSS 0 – 6 
Relapse-free time before baseline 3 months Steroid-free time before baseline 3 months 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 14 Words / characters describing the 
eligibility criteria 
91 / 504 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 8 (4) Number of patients (females) 20 (11) 
Mean age (SD) in years 38 (11.709) Mean age (SD) in years 35 (9.078) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 6.37 (2.771) Mean MS duration (SD) in years 7.9 (4.306) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.06 (0.693) Mean pre-trial ARR (SD) 1.174 (0.952) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.81 (1.628) Mean score on the EDSS (SD) 3.176 (0.952) 





study ID #10 




Title Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized 
controlled trial 
Authors The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI 
Analysis Group 
Date of publication Jul 1995 Journal / 
Reference 
Neurology 45 (7): 1277-85 
 
Neurology 43: 655-667 
Score on the OQS 4 





Placebo; 1.6 MIU IFNbeta-1b; 8 MIU IFNbeta-1b  
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
1.12 (1.329) Number of patients 
considered for calculation 
of trial ARR 
123 





Age 18 – 50 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 10 Words / characters describing the 
eligibility criteria 
106 / 546 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 123 (88) Number of patients (females) 372 (259) 
Mean age (SD) in years 36 (6.654) Mean age (SD) in years 35.498 (7.087) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 3.9 (3.327) Mean MS duration (SD) in years 4.436 (4.14) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.8 (0.555) Mean pre-trial ARR (SD) 1.716 (0.795) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.8 (1.109) Mean score on the EDSS (SD) 2.9 (2.771) 





study ID #11 




Title Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis 
Authors Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Aström M, 
Gjörstrup P, Ekholm S 
Date of publication Oct 1996 Journal / 
Reference 
Neurology 47 (4): 895-900 
Score on the OQS 4 





Placebo; 2.5 mg/d Linomide 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.087 Number of patients 
considered for calculation 
of trial ARR 
14 





Age 18 – 50 Score on the EDSS 1 – 4 
Relapse-free time before baseline 1 month Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 5 Words / characters describing the 
eligibility criteria 
54 / 269 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 14 (11) Number of patients (females) 28 (20) 
Mean age (SD) in years 32 Mean age (SD) in years 31.5 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 2.14 (2.17) Mean MS duration (SD) in years 3.57 (3.841) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.57 (0.468) Mean pre-trial ARR (SD) 1.588 (0.58) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.21 (0.973) Mean score on the EDSS (SD) 2.265 (0.92) 





study ID #12 




Title Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis 
Authors Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, 
Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, 
Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, 
Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. 
Date of publication Mar 1996 Journal / 
Reference 
Ann Neurol 39 (3): 285-94 
 
Score on the OQS 4 





Placebo; 30 µg/w IFNbeta-1a 
(1:1) 
Trial ARR of the 
placebo group (SD) 
0.82 Number of patients 
considered for calculation 
of trial ARR 
143 





Age 18 – 55 Score on the EDSS 1 – 3.5 
Relapse-free time before baseline 2 months Steroid-free time before baseline 2 months 
Minimum pre-trial ARR 0.667 Time considered for calculation of 
pre-trial ARR in years 
3 
Number of eligibility criteria 14 Words / characters describing the 
eligibility criteria 
107 / 643 
Eligible courses of MS Relapsing  
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 143 (103) Number of patients (females) 301 (221) 
Mean age (SD) in years 36.9 (7.653) Mean age (SD) in years 36.795 (7.389) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 6.4 (5.86) Mean MS duration (SD) in years 6.505 (5.81) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.3 (0.837) Mean score on the EDSS (SD) 2.353 (0.795) 





study ID #13 




Title Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-
controlled, double-blind study 
Authors Lycke J, Svennerholm B, Hjelmquist E, Frisén L, Badr G, Andersson M, Vahlne A, 
Andersen O 
Date of publication Mar 1996 Journal / 
Reference 
J Neurol 243 (3): 214-24 
Score on the OQS 4 





Placebo; 3x 800 mg/d Acyclovir 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.57 Number of patients 
considered for calculation 
of trial ARR 
30 





Age 18 – 45 Score on the EDSS 0 – 3.5 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 12 Words / characters describing the 
eligibility criteria 
135 / 821 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 30 (23) Number of patients (females) 60 (40) 
Mean age (SD) in years 33.13 (6.956) Mean age (SD) in years 32.78 (7.21) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 6.17 (6.573) Mean MS duration (SD) in years 5.8 (6.42) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.69 (0.657) Mean pre-trial ARR (SD) 1.72 (0.769) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 1.88 (0.603) Mean score on the EDSS (SD) 1.84 (0.715) 





study ID #14 




Title Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in 
relapsing-remitting multiple sclerosis 
Authors Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B 
Date of publication Mar 1997 Journal / 
Reference 
Lancet 349 (9052): 589-93 
Score on the OQS 5 





Placebo; 0.15 – 0.2 mg/kg/month IVIg 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.26 (2.223) Number of patients 
considered for calculation 
of trial ARR 
73 





Age 15 – 64 Score on the EDSS 1 – 6 
Relapse-free time before baseline - Steroid-free time before baseline 2 weeks 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 10 Words / characters describing the 
eligibility criteria 
142 / 803 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 73 (54) Number of patients (females) 148 (111) 
Mean age (SD) in years 37.3 (10.026) Mean age (SD) in years 36.996 (10.292) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 7.3 (5.667) Mean MS duration (SD) in years 7.047 (5.262) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.37 (1.744) Mean score on the EDSS (SD) 3.3 (1.541) 





study ID #15 




Title Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple 
sclerosis: 24-month clinical and MRI outcome 
Authors Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, Morino S, 
Morra VB, Bozzao A, Calo A, Bernini ML, Gambi D, Prencipe M  
Date of publication Mar 1997 Journal / 
Reference 
J Neurol 244 (3): 153-9 
 
Score on the OQS 5 





Placebo; 12x 8 mg/m²/month Mitoxantrone 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.31 (0.95) Number of patients 
considered for calculation 
of trial ARR 
24 





Age 18 – 45 Score on the EDSS 2 – 5 
Relapse-free time before baseline - Steroid-free time before baseline 3 months 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 20 Words / characters describing the 
eligibility criteria 
128 / 779 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 24 (18) Number of patients (females) 51 (35) 
Mean age (SD) in years 28.7 (6.5) Mean age (SD) in years 29.865 (6.276) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 5 (3) Mean MS duration (SD) in years 5.371 (2.991) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.4 (0.55) Mean pre-trial ARR (SD) 1.4 (0.571) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.5 (1.2) Mean score on the EDSS (SD) 3.553 (0.768) 





study ID #16 




Title A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization 
in multiple sclerosis 
Authors Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher CA, Lublin 
FD, Knobler RL, Trantas F, Kelley L, Smith CR, La Rocca N, Lopez S 
Date of publication Feb 1997 Journal / 
Reference 
Neurology 48 (2): 312-4 
Score on the OQS 3 





Placebo; 1x Influenza-vaccination 
(1:2) 
Trial ARR of the 
placebo group (SD) 
0.22 Number of patients 
considered for calculation 
of trial ARR 
54 





Age - Score on the EDSS 0 – 6 
Relapse-free time before baseline 4 weeks Steroid-free time before baseline 4 weeks 
 
Minimum pre-trial ARR - Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 9 Words / characters describing the 
eligibility criteria 
92 / 516 
 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 54 Number of patients (females) 103 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #17 




Title Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of 
a randomized, double-blind, placebo-controlled, MR-monitored phase II trial 
Authors Van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, 
Rudge P, McDougall A, McLeod JG, Adèr HJ, Polman CH 
Date of publication Aug 1997 Journal / 
Reference 
Neurology 49 (2): 351-7 
 
Multiple Sclerosis 1 (6): 339-342 
Score on the OQS 4 





Placebo; 6x 50 mg/month cM-T412 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.8 (1.393) Number of patients 
considered for calculation 
of trial ARR 
36 





Age 18 – 55 Score on the EDSS 3 – 7 
Relapse-free time before baseline 2 months Steroid-free time before baseline 4 weeks 
Minimum pre-trial ARR 2 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 25 Words / characters describing the 
eligibility criteria 
253 / 1466 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 36 (23) Number of patients (females) 71 (39) 
Mean age (SD) in years 36.8 (6.7) Mean age (SD) in years 36.849 (6.901) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 6.4 (6.2) Mean MS duration (SD) in years 6.548 (5.872) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 2.1 (1) Mean pre-trial ARR (SD) 1.804 (1.038) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #18 




Title Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses 
Authors Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer 
Y, Sarova-Pinhas I 
Date of publication Feb 1998 Journal / 
Reference 
Neurology 50 (2): 398-402 
Score on the OQS 5 





Placebo; 0.4 g/kg/d IVIg every other month 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.61 (0.857) Number of patients 
considered for calculation 
of trial ARR 
20 





Age 18 – 60 Score on the EDSS 0 – 6 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 0.5 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 10 Words / characters describing the 
eligibility criteria 
68 / 386 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 20 (16) Number of patients (females) 40 (32) 
Mean age (SD) in years 33.8 (10.733) Mean age (SD) in years 34.6 (9.987) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 3.95 (2.862) Mean MS duration (SD) in years 4.025 (2.761) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.55 (0.76) Mean pre-trial ARR (SD) 1.7 (0.982) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.82 (1.655) Mean score on the EDSS (SD) 2.86 (1.771) 





study ID #19 




Title Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical 
effect on multiple sclerosis relapse rate and degree of disability 
Authors Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch 
HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS 
Date of publication Mar 1998 Journal / 
Reference 
Neurology 50 (3): 701-8 
 
Neurology  45 (7): 1268-76 Score on the OQS 4 





Placebo; 20 mg/d Glatiramer Acetate 
(1:1) 
 
Trial ARR of the 
placebo group (SD) 
0.81 Number of patients 
considered for calculation 
of trial ARR 
126 





Age 18 – 45 Score on the EDSS 0 – 5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 21 Words / characters describing the 
eligibility criteria 
157 / 883 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 126 (96) Number of patients (females) 251 (184) 
Mean age (SD) in years 34.33 (6.49) Mean age (SD) in years 34.455 (6.225) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 6.64 (5.09) Mean MS duration (SD) in years 6.944 (4.971) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.465 (0.565) Mean pre-trial ARR (SD) 1.46 (0.597) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.42 (1.28) Mean score on the EDSS (SD) 2.619 (1.25) 





study ID #20 




Title The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis 
Authors Noseworthy JH, O'Brien P, Erickson BJ, Lee D, Sneve D, Ebers GC, Rice GP, Auty A, 
Hader WJ, Kirk A, Duquette P, Carter J, Francis G, Metz L, Shuster E  
Date of publication Nov 1998 Journal / 
Reference 
Neurology 51 (5): 1342-52 
Score on the OQS 5 





Placebo; 1 week 500 mg/d Sulfasalazine, an additional 500 mg/d per week up to 2 g/d 
Sulfasalazine 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.1 Number of patients 
considered for calculation 
of trial ARR 
79 





Age 18+ Score on the EDSS 1 – 4 
Relapse-free time before baseline - Steroid-free time before baseline 4 weeks 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 14 Words / characters describing the 
eligibility criteria 
149 / 889 
Eligible courses of MS RRMS + SPMS + PPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 79 (48) Number of patients (females) 151 (105) 
Mean age (SD) in years 26.5 Mean age (SD) in years 27.692 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 4 Mean MS duration (SD) in years 4.954 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.5 Mean pre-trial ARR (SD) 1.5 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2 Mean score on the EDSS (SD) 2 





study ID #21 




Title Randomised double-blind placebo-controlled study of interferon beta-1a in 
relapsing/remitting multiple sclerosis  
Authors PRISMS Study Group 
Date of publication Nov 1998 Journal / 
Reference 
Lancet 352 (9139): 1498-504 
Score on the OQS 5 





Placebo; 3x 22 µg/w IFNbeta-1a; 3x 44 µg/w IFNbeta-1a 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
1.28 
 
Number of patients 
considered for calculation 
of trial ARR 
187 







Age - Score on the EDSS 0 – 5 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 9 Words / characters describing the 
eligibility criteria 
77 / 448 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 187 (140) Number of patients (females) 560 (386) 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years 34.6 (28.8; 40.4) Median age (IQR) in years 34.9 (29.1; 
40.4) 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years 4.3 (2.4; 8.4) Median MS duration (IQR) in years 5.3 (2.8; 10) 
Mean pre-trial ARR (SD) 1.5 (0.65) Mean pre-trial ARR (SD) 1.5 (0.6) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.4 (1.2) Mean score on the EDSS (SD) 2.5 (1.2) 





study ID #22 




Title Intravenous Immunoglobulins in Multiple Sclerosis: Results of the Austrian Immunoglobulin 
in Multiple Sclerosis (AIMS) Trial 
Authors Deisenhammer F, Fazekas F, Strasser-Fuchs S, Nahler G, Mamoli B, AIMS Study Group 
Date of publication Nov 1999 Journal / 
Reference 
Infusionsther Transfusionsmed 26 
(Suppl.2): 42-47 
Score on the OQS 5 





Placebo; 0.15 – 0,2 g/kg/month IVIg 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.26 (2.2) Number of patients 
considered for calculation 
of trial ARR 
73 





Age 15 – 65 Score on the EDSS 1 – 6 
Relapse-free time before baseline - Steroid-free time before baseline 2 weeks 
Minimum pre-trial ARR - Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 10 Words / characters describing the 
eligibility criteria 
147 / 734 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 73 (54) Number of patients (females) 148 (111) 
Mean age (SD) in years 37.7 (9.8) Mean age (SD) in years 36.996 (10.079) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 7.3 (5.7) Mean MS duration (SD) in years 7.047 (5.16) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.4 (0.9) Mean pre-trial ARR (SD) 1.349 (0.898) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.3 (1.7) Mean score on the EDSS (SD) 3.3 (1.55) 





study ID #23 




Title TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study 
Authors The Lenercept Multiple Sclerosis Study Group and The University of British Columbia 
MS/MRI Analysis Group 
Date of publication Aug 1999 Journal / 
Reference 
Neurology 53 (3): 457-65 
Score on the OQS 5 





Placebo; 10 mg/4w Lenercept; 50 mg/4w Lenercept; 100 mg/4w Lenercept 
(1:1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.98 Number of patients 
considered for calculation 
of trial ARR 
43 





Age 18 – 55 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline 4 weeks Steroid-free time before baseline 4 weeks 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 11 Words / characters describing the 
eligibility criteria 
154 / 843 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 44 (29) Number of patients (females) 168 (124) 
Mean age (SD) in years 36.5 Mean age (SD) in years 35.288 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.35 Mean pre-trial ARR (SD) 1.411 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.45 Mean score on the EDSS (SD) 2.583 





study ID #24 




Title Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis 
Authors Myhr KM, Riise T, Green Lilleås FE, Beiske TG, Celius EG, Edland A, Jensen D, Larsen 
JP, Nilsen R, Nortvedt MW, Smievoll AI, Vedeler C, Nyland HI 
Date of publication Mar 1999 Journal / 
Reference 
Neurology 52 (5): 1049-56 
Score on the OQS 4 





Placebo; 3x 4.5 MIU/w IFNalpha-2a; 3x 9 MIU/w IFNalpha-2a 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.88 Number of patients 
considered for calculation 
of trial ARR 
32 





Age 18 – 50 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline - Steroid-free time before baseline 1 month 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 14 Words / characters describing the 
eligibility criteria 
102 / 593 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 33 (23) Number of patients (females) 97 (69) 
Mean age (SD) in years 36.7 Mean age (SD) in years 34.69 
Median age (IQR) in years 36 Median age (IQR) in years - 
Mean MS duration (SD) in years 5.5 Mean MS duration (SD) in years 6.853 
Median MS duration (IQR) in years 5 Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.42 Mean pre-trial ARR (SD) 1.338 
Median pre-trial ARR (IQR) 1.5 Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.73 Mean score on the EDSS (SD) 2.842 





study ID #25 




Title Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study 
Authors The Once Weekly Interferon for MS Study Group 
Date of publication Sep 1999 Journal / 
Reference 
Neurology 53 (4): 679-86 
Score on the OQS 5 





Placebo; 22 µg/w IFNbeta-1a; 44 µg/w IFNbeta-1a 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
1.174 (1.25) Number of patients 
considered for calculation 
of trial ARR 
100 





Age 18 – 50 Score on the EDSS 0 – 5 
Relapse-free time before baseline 8 weeks Steroid-free time before baseline 8 weeks 
Minimum pre-trial ARR 0.5 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 17 Words / characters describing the 
eligibility criteria 
122 / 629 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 100 (74) Number of patients (females) 293 (213) 
Mean age (SD) in years 34.9 (7.8) Mean age (SD) in years 35.263 (7.486) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 6.3 (4.7) Mean MS duration (SD) in years 6.628 (5.026) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.2 (0.6) Mean pre-trial ARR (SD) 1.2 (0.599) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.6 (1.3) Mean score on the EDSS (SD) 2.632 (1.3) 





study ID #26 




Title Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple 
sclerosis patients. A two-year study 
Authors Patti F, L'Episcopo MR, Cataldi ML, Reggio A 
Date of publication Nov 1999 Journal / 
Reference 
Acta Neurol Scand 100 (5): 283-9 
Score on the OQS 4 





Placebo; 3x 6 MIU/w IFNbeta 
(1:1) 
Trial ARR of the 
placebo group (SD) 
0.31 Number of patients 
considered for calculation 
of trial ARR 
29 





Age 18 – 45 Score on the EDSS 0 – 3.5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 17 Words / characters describing the 
eligibility criteria 
166 / 863 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 29 (17) Number of patients (females) 58 (34) 
Mean age (SD) in years 36.6 Mean age (SD) in years 36.6 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 9.7 Mean MS duration (SD) in years 9.8 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 0.95 Mean pre-trial ARR (SD) 0.925 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.1 Mean score on the EDSS (SD) 3.08 





study ID #27 




Title A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting 
multiple sclerosis 
Authors Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E 
Date of publication Jan 1999 Journal / 
Reference 
Proc Assoc Am Physicians 111 (1): 35-
44 
Score on the OQS 5 





Placebo; 0.07 mg/kg/d Cladribine 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.34 (1.145) Number of patients 
considered for calculation 
of trial ARR 
25 





Age - Score on the EDSS 0 – 6.5 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 13 Words / characters describing the 
eligibility criteria 
101 / 605 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 25 (18) Number of patients (females) 52 (36) 
Mean age (SD) in years 39.8 Mean age (SD) in years 41.669 
Median age (IQR) in years 41 (36.5; 44) Median age (IQR) in years - 
Mean MS duration (SD) in years 9.1 Mean MS duration (SD) in years 9.671 
Median MS duration (IQR) in years 9 (3.5; 12.5) Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.8 Mean score on the EDSS (SD) 3.852 





study ID #28 




Title The effect of anti-alpha4 integrin antibody on brain lesion activity in MS 
Authors Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, 
Palace J, Sharrack B, Swingler R, Young C, Moseley IF, MacManus DG, Donoghue S, 
Miller DH 
Date of publication Aug 1999 Journal / 
Reference 
Neurology 53 (3): 466-72 
Score on the OQS 4 





Placebo; 3 mg/kg Natalizumab 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.052 Number of patients 
considered for calculation 
of trial ARR 
31 





Age 18 – 55 Score on the EDSS 2 – 7 
Relapse-free time before baseline 4 weeks Steroid-free time before baseline 4 weeks 
Minimum pre-trial ARR 1.333 Time considered for calculation of 
pre-trial ARR in years 
1.5 
Number of eligibility criteria 21 Words / characters describing the 
eligibility criteria 
132 / 803 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 35 (21) Number of patients (females) 72 (46) 
Mean age (SD) in years 40.8 Mean age (SD) in years 40.338 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 9.933 Mean MS duration (SD) in years 9.848 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 4.7 Mean score on the EDSS (SD) 4.803 





study ID #29 




Title Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS 
Authors Brod SA, Lindsey JW, Vriesendorp FS, Ahn C, Henninger E, Narayana PA, Wolinsky JS 
Date of publication Sep 2001 Journal / 
Reference 
Neurology 57 (5): 845-52 
Score on the OQS 4 





Placebo; 10 kIU/2d IFNalpha-2a, 30 kIU/2d IFNalpha-2a 
(1:1:1) 
 
Trial ARR of the 
placebo group (SD) 
0.267 Number of patients 
considered for calculation 
of trial ARR 
10 





Age 18 – 55 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline - Steroid-free time before baseline 1 month 
Minimum pre-trial ARR - Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 10 Words / characters describing the 
eligibility criteria 
80 / 439 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 10 (8) Number of patients (females) 29 (24) 
Mean age (SD) in years 43 (5.4) Mean age (SD) in years 42.559 (7.185) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 0.5 (0.25) Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.2 (1.7) Mean score on the EDSS (SD) 2.662 (1.424) 





study ID #30 




Title European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the 
effects of glatiramer acetate on magnetic resonance imaging--measured disease activity 
and burden in patients with relapsing multiple sclerosis 
Authors Comi G, Filippi M, Wolinsky JS 
Date of publication Mar 2001 Journal / 
Reference 
Ann Neurol 49 (3): 290-7 
Score on the OQS 5 





Placebo; 20 mg/d Glatiramer Acetate 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.21 Number of patients 
considered for calculation 
of trial ARR 
120 





Age 18 – 50 Score on the EDSS 0 – 5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 0.5 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 26 Words / characters describing the 
eligibility criteria 
184 / 975 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 120 Number of patients (females) 239 
Mean age (SD) in years 34 (7.5) Mean age (SD) in years 34.05 (7.435) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 8.3 (5.5) Mean MS duration (SD) in years 8.101 (5.492) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.25 (0.7) Mean pre-trial ARR (SD) 1.325 (0.808) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.4 (1.2) Mean score on the EDSS (SD) 2.35 (1.15) 





study ID #31 




Title A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in 
MS 
Authors Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, Andersen O, Christensen T, 
Ekholm S, Haahr S, Höllsberg P et al. 
Date of publication Jan 2002 Journal / 
Reference 
Neurology 58 (1): 31-6 
 
Score on the OQS 4 





Placebo; 3 g/d Valacyclovir 
(1:1) 
Trial ARR of the 
placebo group (SD) 
1.407 Number of patients 
considered for calculation 
of trial ARR 
34 





Age 18 – 55 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 25 Words / characters describing the 
eligibility criteria 
207 / 1156 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 34 (21) Number of patients (females) 70 (44) 
Mean age (SD) in years 33.1 (7.2) Mean age (SD) in years 34.6 (8.7) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 9.5 (5.8) Mean MS duration (SD) in years 9.5 (6) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.35 (0.45) Mean pre-trial ARR (SD) 1.3 (0.45) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #32 




Title No difference in efficacy of two different doses of intravenous immunoglobulins in MS: 
clinical and MRI assessment 
Authors Lewańska M, Siger-Zajdel M, Selmaj K 
Date of publication Nov 2002 Journal / 
Reference 
Eur J Neurol 9 (6): 565-72 
Score on the OQS 4 





Placebo; 0.2 g/kg/d IVIg; 0.4 g/kg/d IVIg 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
1.24 (0.75) Number of patients 
considered for calculation 
of trial ARR 
18 





Age 18 – 55 Score on the EDSS 0 – 6.5 
Relapse-free time before baseline 3 months Steroid-free time before baseline 3 months 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 20 Words / characters describing the 
eligibility criteria 
147 / 801 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 17 (7) Number of patients (females) 49 (29) 
Mean age (SD) in years 41.8 (6.98) Mean age (SD) in years 37.206 (7.907) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 7.5 (4.7) Mean MS duration (SD) in years 8.518 (6.15) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.97 (1.58) Mean score on the EDSS (SD) 2.99 (2.193) 





study ID #33 




Title A controlled trial of natalizumab for relapsing multiple sclerosis 
Authors Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme 
AJ, Dalton CM, Miszkiel KA, O'Connor PW; International Natalizumab Multiple Sclerosis 
Trial Group 
Date of publication Jan 2003 Journal / 
Reference 
N Engl J Med 348 (1): 15-23 
Score on the OQS 4 





Placebo; 3 mg/kg Natalizumab; 6 mg/kg Natalizumab 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.507 Number of patients 
considered for calculation 
of trial ARR 
71 





Age 18 – 65 Score on the EDSS 2 – 6.5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria - Words / characters describing the 
eligibility criteria 
117 / 636 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 71 (46) Number of patients (females) 213 (152) 
Mean age (SD) in years 42.9 Mean age (SD) in years 43.563 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 10.2 Mean MS duration (SD) in years 11.655 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.5 Mean pre-trial ARR (SD) 1.501 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 4.4 Mean score on the EDSS (SD) 4.301 










Title Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with 
multiple sclerosis. 
Authors Wroe SJ 
Date of publication May 2005 Journal / 
Reference 
J Int Med Res 33 (3): 309-18 
Score on the OQS 4 





Placebo; IFNbeta-1b 8 MIU 
(1:2) 
Trial ARR of the 
placebo group (SD) 
1.091 Number of patients 
considered for calculation 
of trial ARR 
33 





Age 18 – 55 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 1 month 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 32 Words / characters describing the 
eligibility criteria 
228 / 1308 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 33 (24) Number of patients (females) 98 (72) 
Mean age (SD) in years 38 Mean age (SD) in years 36.01 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.235 Mean pre-trial ARR (SD) 1.298 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.09 Mean score on the EDSS (SD) 2.977 





study ID #35 




Title Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients 
with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-
controlled study 
Authors Filippi M, Wolinsky JS, Comi G; CORAL Study Group 
Date of publication Jan 2006 Journal / 
Reference 
Lancet Neurol 5 (3): 213-20 
Score on the OQS 5 





Placebo; 5 mg/d Glatiramer Acetate; 50 mg/d Glatiramer Acetate 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.568 Number of patients 
considered for calculation 
of trial ARR 
548 





Age 18 – 50 Score on the EDSS 0 – 5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 28 Words / characters describing the 
eligibility criteria 
212 / 1209 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 548 (401) Number of patients (females) 1644 (1219) 
Mean age (SD) in years 36.6 (7.7) Mean age (SD) in years 36.498 (7.675) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 7.7 (6.2) Mean MS duration (SD) in years 7.662 (6.167) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1 year period:  
1.5 (0.8) 
 
2 year period:  
1.1 (0.6) 
Mean pre-trial ARR (SD) 1 year period:  
1.5 (0.734) 
 
2 year period:  
1.084 (0.584) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.3 (1.2) Mean score on the EDSS (SD) 2.266 (1.135) 





study ID #36 




Title Oral fingolimod (FTY720) for relapsing multiple sclerosis. 
Authors Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, 
Karlsson G, Radue EW 
Date of publication Sep 2006 Journal / 
Reference 
N Engl J Med 355 (11): 1124-40 
 Score on the OQS 5 





Placebo; 1.25 mg/d Fingolimod; 5 mg/d Fingolimod 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.77 Number of patients 
considered for calculation 
of trial ARR 
92 





Age 18 – 60 Score on the EDSS 0 – 6 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
Complex 
Number of eligibility criteria 15 Words / characters describing the 
eligibility criteria 
191 / 1035 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 92 (61) Number of patients (females) 277 (196) 
Mean age (SD) in years 37.1 Mean age (SD) in years 37.801 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 8.4 Mean MS duration (SD) in years 8.833 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1 year period: 
1.2 
 
2 year period: 
0.9 
Mean pre-trial ARR (SD) 1 year period: 
1.267 
 
2 year period: 
0.933 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.6 Mean score on the EDSS (SD) 2.6 





study ID #37 




Title A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with 
relapses 
Authors O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart 
JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia 
MS/MRI Research Group 
Date of publication Mar 2006 Journal / 
Reference 
Neurology 66 (6): 894-900 
Score on the OQS 4 





Placebo; 7 mg/d Teriflunomide; 14 mg/d Teriflunomide 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.81 (1.22) Number of patients 
considered for calculation 
of trial ARR 
61 





Age 18 – 65 Score on the EDSS 0 – 6 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR Complex Time considered for calculation of 
pre-trial ARR in years 
Complex 
Number of eligibility criteria 10 Words / characters describing the 
eligibility criteria 
95 / 528 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 61 (41) Number of patients (females) 179 (132) 
Mean age (SD) in years 39.2 (8.7) Mean age (SD) in years 39.793 (8.995) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 8.6 (7.9) Mean MS duration (SD) in years 9.148 (7.727) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) 1 Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #38 




Title A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis 
Authors Polman CH, O'Connor PW, Havrdová E, Hutchinson M, Kappos L, Miller DH, Phillips JT, 
Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM 
Investigators 
Date of publication Mar 2006 Journal / 
Reference 
N Engl J Med 354 (9): 899-910 
Score on the OQS 5 





Placebo; 300 mg/4w Natalizumab 
(1:2) 
Trial ARR of the 
placebo group (SD) 
0.64 Number of patients 
considered for calculation 
of trial ARR 
315 





Age 18 – 50 Score on the EDSS 0 – 5 
Relapse-free time before baseline 50 days Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 15 Words / characters describing the 
eligibility criteria 
172 / 969 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 315 (211) Number of patients (females) 942 (660) 
Mean age (SD) in years 36.7 (7.8) Mean age (SD) in years 36 (8.3) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years 6 Median MS duration (IQR) in years 5 
Mean pre-trial ARR (SD) 1.5 (0.77) Mean pre-trial ARR (SD) 1.52 (0.86) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.3 (1.2) Mean score on the EDSS (SD) 2.3 (1.2) 





study ID #39 




Title Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in 
multiple sclerosis. 
Authors Broadley SA, Vanags D, Williams B, Johnson B, Feeney D, Griffiths L, Shakib S, Brown G, 
Coulthard A, Mullins P, Kneebone C 
Date of publication Nov 2008 Journal / 
Reference 
Mult Scler 15 (3): 329-36 
Score on the OQS 5 





Placebo; 5 mg/w Chaperonin10; 10 mg/w Chaperonin10 
(1:2:2) 
Trial ARR of the 
placebo group (SD) 
0.395 Number of patients 
considered for calculation 
of trial ARR 
11 





Age 18 – 60 Score on the EDSS 0 – 6.5 
Relapse-free time before baseline 4 weeks Steroid-free time before baseline - 
Minimum pre-trial ARR - Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 22 Words / characters describing the 
eligibility criteria 
213 / 1201 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 11 (7) Number of patients (females) 50 (37) 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years 49 Median age (IQR) in years 46 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #40 




Title Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting 
multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb 
study 
Authors Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdová E, 
Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group 
Date of publication Jun 2008 Journal / 
Reference 
Lancet 371 (9630): 2085-92 
Score on the OQS 5 





Placebo; 0.3 mg Laquinimod; 0.6 mg Laquinimod 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.77 (1.25) Number of patients 
considered for calculation 
of trial ARR 
102 





Age 18 – 50 Score on the EDSS 1 – 5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 31 Words / characters describing the 
eligibility criteria 
245 / 1437 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 102 Number of patients (females) 306 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.37 (0.56) Mean pre-trial ARR (SD) 1.447 (0.684) 
Median pre-trial ARR (IQR) 1 Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.5 (1.1) Mean score on the EDSS (SD) 2.367 (1.067) 





study ID #41 




Title Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial 
Authors Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, 
Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI 
Research Group 
Date of publication Jul 2008 Journal / 
Reference 
Neurology 71 (4): 265-71 
 
Score on the OQS 5 





Placebo; 0.2 g/kg/4w IVIg-C 10%; 0.4 g/kg/4w IVIg-C 10% 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.5 (1.02) Number of patients 
considered for calculation 
of trial ARR 
41 





Age 18 – 55 Score on the EDSS 0 – 4.5 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 2 Words / characters describing the 
eligibility criteria 
83 / 430 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 41 Number of patients (females) 127 (95) 
Mean age (SD) in years 33 (8.7) Mean age (SD) in years 33.082 (8.038) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 2.3 (1.5) Mean MS duration (SD) in years 2.606 (1.851) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1.4 (0.8) Mean pre-trial ARR (SD) 1.469 (1.066) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.1 (1.2) Mean score on the EDSS (SD) 1.996 (1.071) 





study ID #42 




Title Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis 
Authors Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, 
Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L; BHT-3009 
Study Group 
Date of publication May 2008 Journal / 
Reference 
Ann Neurol 63 (5): 611-20 
 
 
Score on the OQS 4 





Placebo; 0.5 mg BHT-3009; 1.5 mg BHT-3009 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.44 Number of patients 
considered for calculation 
of trial ARR 
87 





Age 18 – 55 Score on the EDSS 0 – 3.5 
Relapse-free time before baseline 50 days Steroid-free time before baseline 50 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 11 Words / characters describing the 
eligibility criteria 
111 / 609 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 87 (62) Number of patients (females) 267 (185) 
Mean age (SD) in years 37.2 Mean age (SD) in years 36.499 
Median age (IQR) in years 37 Median age (IQR) in years - 
Mean MS duration (SD) in years 6.242 Mean MS duration (SD) in years 6.439 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 0.95 Mean pre-trial ARR (SD) 0.999 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.48 Mean score on the EDSS (SD) 2.449 





study ID #43 




Title B-cell depletion with rituximab in relapsing-remitting multiple sclerosis 
Authors Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, 
Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group 
Date of publication Feb 2008 Journal / 
Reference 
N Engl J Med 358 (7): 676-88 
Score on the OQS 4 





Placebo; 1 g Rituximab 
(1:2) 
Trial ARR of the 
placebo group (SD) 
0.7 (1.05) Number of patients 
considered for calculation 
of trial ARR 
35 





Age 18 – 55 Score on the EDSS 0 – 5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 14 Words / characters describing the 
eligibility criteria 
90 / 580 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 35 (29) Number of patients (females) 104 (81) 
Mean age (SD) in years 41.5 (8.5) Mean age (SD) in years 40.239 (8.639) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 9.6 (7.1) Mean MS duration (SD) in years 9.6 (6.609) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) 1 Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #44 




Title Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a 
multicentre, randomised, double-blind, placebo-controlled phase IIb study 
Authors Kappos L, Gold R, Miller DH, Macmanus DG, Havrdová E, Limmroth V, Polman CH, 
Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, 
Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators 
Date of publication Oct 2008 Journal / 
Reference 
Lancet 372 (9648): 1463-72 
Score on the OQS 4 





Placebo; 120 mg/d Fumarat per os; 360 mg/d Fumarat per os; 720 mg/d Fumarat per os 
(1:1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.65 (1.193) Number of patients 
considered for calculation 
of trial ARR 
65 





Age 18 – 55 Score on the EDSS 0 – 5 
Relapse-free time before baseline 50 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 37 Words / characters describing the 
eligibility criteria 
226 / 1387 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 65 (36) Number of patients (females) 256 (164) 
Mean age (SD) in years 35.6 (8.2) Mean age (SD) in years 35.993 (9.266) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years 6 (4; 11) Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) 1 Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.67 (1.23) Mean score on the EDSS (SD) 2.642 (1.18) 





study ID #45 




Title Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, 
placebo-controlled, exploratory study 
Authors Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem 
MA, De Keyser J 
Date of publication May 2008 Journal / 
Reference 
J Neurol Neurosurg Psychiatry 79 (9): 
1027-31 
Score on the OQS 4 





Placebo; 20 mg/d Fluoxetine 
(1:1) 
Trial ARR of the 
placebo group (SD) 
0.687 Number of patients 
considered for calculation 
of trial ARR 
19 





Age 18 – 65 Score on the EDSS 0 – 6 
Relapse-free time before baseline - Steroid-free time before baseline 8 weeks 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
Complex 
Number of eligibility criteria 15 Words / characters describing the 
eligibility criteria 
124 / 708 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 19 (10) Number of patients (females) 38 (20) 
Mean age (SD) in years 38 (9) Mean age (SD) in years 39.5 (9.506) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 11 (8) Mean MS duration (SD) in years 11 (7.414) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #46 




Title Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in 
patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-
controlled, randomised, dose-ranging study 
Authors Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH; 
Ustekinumab MS Investigators 
Date of publication Sep 2008 Journal / 
Reference 
Lancet Neurol 7 (9): 796-804 
Score on the OQS 5 





Placebo; 27 mg/4w Ustekinumab; 90 mg/8w Ustekinumab; 90 mg/4w Ustekinumab; 180 
mg/4w Ustekinumab 
(1:1:1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.374 Number of patients 
considered for calculation 
of trial ARR 
49 





Age 18 – 65 Score on the EDSS 0 – 6.5 
Relapse-free time before baseline 1 month Steroid-free time before baseline 1 month 
Minimum pre-trial ARR Complex Time considered for calculation of 
pre-trial ARR in years 
complex 
Number of eligibility criteria 15 Words / characters describing the 
eligibility criteria 
121 / 690 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 49 (37) Number of patients (females) 249 (175) 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years 34 Median age (IQR) in years 38 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years 1.9 Median MS duration (IQR) in years 1.9 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #47 




Title Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? 
Authors Barkhof F, Hulst HE, Drulović J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 
Investigators 
Date of publication Mar 2010 Journal / 
Reference 
Neurology 74 (13): 1033-40 
Score on the OQS 5 





Placebo; 30 mg/d Ibudilast; 60 mg/d Ibudilast 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.9 (1) Number of patients 
considered for calculation 
of trial ARR 
90 





Age 18 – 55 Score on the EDSS 0 – 5 
Relapse-free time before baseline - Steroid-free time before baseline 45 days 
Minimum pre-trial ARR - Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 19 Words / characters describing the 
eligibility criteria 
134 / 895 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 100 (66) Number of patients (females) 292 (1.95) 
Mean age (SD) in years 35.7 (8.8) Mean age (SD) in years 35.803 (9.139) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years 4.7 (2.2; 9) Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) 1 Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.3 (1.2) Mean score on the EDSS (SD) 3.334 (1.263) 





study ID #48 




Title A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis 
Authors Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, 
Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group 
Date of publication Jan 2010 Journal / 
Reference 
N Engl J Med 362 (5): 416-26 
Score on the OQS 5 





Placebo; 3.5 mg/kg/96w Cladribine; 5.25 mg/kg/96w Cladribine 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.33 (0.48) Number of patients 
considered for calculation 
of trial ARR 
437 





Age - Score on the EDSS 0 – 5.5 
Relapse-free time before baseline 4 weeks Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 16 Words / characters describing the 
eligibility criteria 
199 / 1083 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 437 (288) Number of patients (females) 1326 (898) 
Mean age (SD) in years 38.7 (9.9) Mean age (SD) in years 38.576 (10.037) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 8.9 (7.4) Mean MS duration (SD) in years 8.711 (7.423) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.9 (1.3) Mean score on the EDSS (SD) 2.902 (1.306) 





study ID #49 




Title A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis 
Authors Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, 
Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group 
Date of publication Jan 2010 Journal / 
Reference 
N Engl J Med 362 (5): 387-40 
Score on the OQS 5 





Placebo; 0.5 mg/d Fingolimod; 1.25 mg/d Fingolimod 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.4 (0.678) Number of patients 
considered for calculation 
of trial ARR 
418  





Age 18 – 55 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
complex 
Number of eligibility criteria 14 Words / characters describing the 
eligibility criteria 
114 / 647 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 418 (298) Number of patients (females) 1272 (889) 
Mean age (SD) in years 37.2 (8.6) Mean age (SD) in years 37.068 (8.767) 
Median age (IQR) in years 37 Median age (IQR) in years - 
Mean MS duration (SD) in years 8.1 (6.4) Mean MS duration (SD) in years 8.167 (6.634) 
Median MS duration (IQR) in years 7 Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1 year period: 
1.5 (0.8) 
 
2 year period: 
1.1 (0.6) 
Mean pre-trial ARR (SD) 1 year period: 
1.467 (0.769) 
 
2 year period: 
1.067 (0.601) 
Median pre-trial ARR (IQR) 1 Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.5 (1.3) Mean score on the EDSS (SD) 2.4 (1.336) 





study ID #50 




Title A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the 
efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with 
relapsing-remitting or secondary progressive multiple sclerosis 
Authors Vollmer TL, Wynn DR, Alam MS, Valdes J 
Date of publication Dec 2010 Journal / 
Reference 
Mult Scler 17 (2): 181-91 
Score on the OQS 4 





Placebo; 200 mg/2w s.c. ABT-874 s.c.; 200 mg/w s.c. ABT-874 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.5 (1.271) Number of patients 
considered for calculation 
of trial ARR 
69 





Age 18 – 60 Score on the EDSS 0 – 6.5 
Relapse-free time before baseline - Steroid-free time before baseline 4 weeks 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
1 
Number of eligibility criteria 13 Words / characters describing the 
eligibility criteria 
129 / 785 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 69 (47) Number of patients (females) 215 (153) 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years 44 Median age (IQR) in years - 
Mean MS duration (SD) in years 8.5 (7.6) Mean MS duration (SD) in years 8.179 (7.145) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.4 (1.5) Mean score on the EDSS (SD) 3.332 (1.632) 





study ID #51 




Title Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple 
sclerosis: further outcomes from the IMPROVE study. 
Authors De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulović JS, Issard D, Shotekov P, 
Gasperini C 
Date of publication Aug 2011 Journal / 
Reference 
J Neurol Sci 312 (1-2): 97-101  
Score on the OQS 2 





Placebo; Interferon beta-1a 44 µg 3x/w 
(1:2) 
Trial ARR of the 
placebo group (SD) 
1.076 (1.933) Number of patients 
considered for calculation 
of trial ARR 
60 





Age 18 – 60 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline - Steroid-free time before baseline - 
Minimum pre-trial ARR 2 Time considered for calculation of 
pre-trial ARR in years 
0.5 
Number of eligibility criteria 5 Words / characters describing the 
eligibility criteria 
47 / 239 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 180 Number of patients (females) 60 
Mean age (SD) in years - Mean age (SD) in years - 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) - Mean score on the EDSS (SD) - 





study ID #52 




Title Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-
controlled, multicentre trial 
Authors Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, 
Glanzman R, Tinbergen J, Hauser SL 
Date of publication Nov 2011 Journal / 
Reference 
Lancet.  378 (9805): 1779-87 
Score on the OQS 5 





2x Placebo; 2x Ocrelizumab 600 mg; 2x Ocrelizumab 2000 mg; Inferferon beta-1a 30 µg 
1x/w 
(1:1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.64 (0.956) Number of patients 
considered for calculation 
of trial ARR 
54 





Age 18 – 55 Score on the EDSS 1 – 6 
Relapse-free time before baseline - Steroid-free time before baseline 28 days 
Minimum pre-trial ARR 0.667 Time considered for calculation of 
pre-trial ARR in years 
3 
Number of eligibility criteria 19 Words / characters describing the 
eligibility criteria 
152 / 910 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 54 (36 Number of patients (females) 218 (141) 
Mean age (SD) in years 38 (8.8) Mean age (SD) in years 37.545 (8.841) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years - Mean MS duration (SD) in years - 
Median MS duration (IQR) in years 4.8 Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) - Mean pre-trial ARR (SD) - 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 3.2 (1.4) Mean score on the EDSS (SD) 3.301 (1.426) 





study ID #53 




Title Randomized trial of oral teriflunomide for relapsing multiple sclerosis. 
Authors O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, 
Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group 
Date of publication Oct 2011 Journal / 
Reference 
N Engl J Med 365 (14): 1293-303 
Score on the OQS 5 





Placebo; Teriflunomide 7 mg/d; Teriflunomide 14 mg/d 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.54 (0.729) Number of patients 
considered for calculation 
of trial ARR 
363 





Age 18 – 55 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline 60 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 71 Words / characters describing the 
eligibility criteria 
589 / 3598 
Eligible courses of MS RRMS + SPMS + PRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 363 (275) Number of patients (females) 1088 (785) 
Mean age (SD) in years 38.4 (9) Mean age (SD) in years 37.866 (8.746) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 8.6 (7.1) Mean MS duration (SD) in years 8.7 (6.86) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1 year period: 
1.4 (0.7) 
 
2 year period: 
1.1 (0.5) 
Mean pre-trial ARR (SD) 1 year period: 
1.367 (0.701) 
 
2 year period: 
1.117 (0.536) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.68 (1.34) Mean score on the EDSS (SD) 2.677 (1.307) 





study ID #54 




Title Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis 
Authors Comi G, Douglas J, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M 
Date of publication Mar 2012 Journal / 
Reference 
N Engl J Med 366 (11): 1000-9 
Score on the OQS 5 





Placebo; 0.6 mg/d Laquinimod 
(1:1) 
Trial ARR of the 
placebo group (SD) 
0.39 (0.707) Number of patients 
considered for calculation 
of trial ARR 
556 





Age 18 – 55 Score on the EDSS 0 – 5.5 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
complex 
Number of eligibility criteria 57 Words / characters describing the 
eligibility criteria 
609 / 3529 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 556 (368) Number of patients (females) 1106 (759) 
Mean age (SD) in years 38.5 (9.1) Mean age (SD) in years 38.699 (9.148) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 8.7 (6.7) Mean MS duration (SD) in years 8.7 (6.797) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1 year period: 
1.3 (0.7) 
 
2 year period: 
0.95 (0.5) 
Mean pre-trial ARR (SD) 1 year period: 
1.25 (0.702) 
 
2 year period: 
0.95 (0.5) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.6 (1.3) Mean score on the EDSS (SD) 2.6 (1.299) 





study ID #55 




Title Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, 
placebo-controlled trial 
Authors Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua P, Yousry T, 
Macmanus D, Montalban X 
Date of publication Jan 2012 Journal / 
Reference 
Lancet Neurol 11 (2): 131-9  
Score on the OQS 5 





Placebo; Firategrast 150 mg 2x/d; Firategrast 600 mg 2x/d; Firategrast 900 mg 2x/d; 
Firategrast 1200 mg 2x/d; 
(2:1:2:2) 
Trial ARR of the 
placebo group (SD) 
0.891 Number of patients 
considered for calculation 
of trial ARR 
99 





Age 18 – 65 Score on the EDSS 0 – 6 
Relapse-free time before baseline 4 weeks Steroid-free time before baseline - 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
2 
Number of eligibility criteria 15 Words / characters describing the 
eligibility criteria 
171 / 916 
Eligible courses of MS RRMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 99 (66) Number of patients (females) 343 (230) 
Mean age (SD) in years 39 (11) Mean age (SD) in years 39.297 (10.762) 
Median age (IQR) in years - Median age (IQR) in years - 
Mean MS duration (SD) in years 5.5 (5.9) Mean MS duration (SD) in years 5.85 (5.916) 
Median MS duration (IQR) in years - Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1 year period: 
1.7 (0.7) 
 
2 year period: 
1.35 (0.485) 
Mean pre-trial ARR (SD) 1 year period: 
1.616 (0.724) 
 
2 year period: 
1.272 (0.475) 
Median pre-trial ARR (IQR) - Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.7 (1.4) Mean score on the EDSS (SD) 2.786 (1.375) 





study ID #56 




Title A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple 
sclerosis 
Authors Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, 
Kira J 
Date of publication Feb 2012 Journal / 
Reference 
Mult Scler 18 (9): 1269-77 
Score on the OQS 5 





Placebo; Fingolimod 0.5 mg/d; Fingolimod 1.25 mg/d 
(1:1:1) 
Trial ARR of the 
placebo group (SD) 
0.99 (1.435) Number of patients 
considered for calculation 
of trial ARR 
57 





Age 18 – 60 Score on the EDSS 0 – 6 
Relapse-free time before baseline 30 days Steroid-free time before baseline 30 days 
Minimum pre-trial ARR 1 Time considered for calculation of 
pre-trial ARR in years 
- 
Number of eligibility criteria 44 Words / characters describing the 
eligibility criteria 
390 / 2262 
Eligible courses of MS RRMS + SPMS 
 
Patient characteristics at baseline (placebo group) 
 
Patient characteristics at baseline (all groups) 
Number of patients (females) 57 (39) Number of patients (females) 171 (118) 
Mean age (SD) in years 35 (8.9) Mean age (SD) in years 35.333 (9.027) 
Median age (IQR) in years 34 Median age (IQR) in years - 
Mean MS duration (SD) in years 8.2 (7.3) Mean MS duration (SD) in years 7.833 (6.505) 
Median MS duration (IQR) in years 6 Median MS duration (IQR) in years - 
Mean pre-trial ARR (SD) 1 year period: 
1.7 (1.6) 
 
2 year period: 
1.4 (1.5) 
Mean pre-trial ARR (SD) 1 year period: 
1.533 (1.206) 
 
2 year period: 
1.217 (1.076) 
Median pre-trial ARR (IQR) 1 Median pre-trial ARR (IQR) - 
Mean score on the EDSS (SD) 2.1 (1.7) Mean score on the EDSS (SD) 2.067 (1.771) 
Median score on the (IQR) 2 Median score on the (IQR) - 
 
 
